
ACADEMIA OPHTHALMOLOGICA BELGICA

Viermaandelijks tijdschrift
Périodique quadri mensuel

INFO





SPECIAL EDITION

Kantoor van uitgifte – 1040 Brussels



NOVEMBER
2026
NOVEMBRE

N° 143

INFO

INFO Nr 143
November - Novembre 2026

Viermaandelijks informatieblad
Périodique quadri mensuel

Verantwoordelijke uitgever /
Editeurs responsable
AOB Office
Nijverheidsstraat 24
Rue de l'Industrie
1040 Brussels

info@ophthalmologia.be
www.ophthalmologia.be

INHOUDSTAFEL / SOMMAIRE

VOORWOORD / PREFACE

5 Voorwoord / Préface

IN MEMORIAM

6-7 Daisy Godts

INGEZONDEN BIJDRAGE / COMMUNICATIONS

8 Champalimaud Foundation Award
9 Rosario Brancato Retina Award
10-11 Time to Help Belgium

MEETINGS & CONGRESSES

12 Enseignement post-universitaire d'ophtalmologie 2025-2026
13-15 COB - Master after Master
16 AMICO 2027
17 WCPOS VI
18 EuCornea 2027
19 IOIS 2027

AGENDA

21-23 Agenda

KLEINE AANKONDIGINGEN / PETITES ANNONCES

25-31 Zoekertjes / Petites annonces

SPECIAL FEATURE > OB 2026

33 OB Organizing Committee
34-37 Voorwoord / Préface OB President
38-40 OB - Our Sponsors
42-44 Programme Overview by Day



OB PROGRAMMA BY DAY

47, 50-51 OBAO
48 AOB Academic Session
49 AOB Lecture - Prof. Dr Alain Gaudric
52-53 BSCRS
54-57 BRS
58-59 BGS
60-61 BSOPRS
62-63 BSA
64-65 PEDLOWNOC
66-67 BOG-SBO
68-69 BBO-UPBMO (Session Ethics)
70-73 BSONT
74 BOV-ABO
75 **AOB Award Ceremony**
78-81 **AOB Free Papers & Rapid Fire Session**

OB E-POSTERS

84-87 AOB E-Posters

INTERACTIVE CLINICAL COURSES - ICC

89-97 Interactive Clincial Courses

WETLABS

98-99 Wetlabs

COMMERCIAL SESSIONS

104 Speaker Corner Short presentations
111 Commercial Satelite Symposia

ACCREDITATIE INFO

114-115 Accreditation Info

ADVERTS

Amgen **112**
Arseus Medical Group **20**
Brailleliga - ligue Braille **24**
CooperVision **76**
EssilorLuxottica **45-46**
Hasa Optix **105, 109**
Laméris **108**
Luce Care **106**
Medic Clean Air **4**
Medic Clean Air/Quality Living **110**
OZOS - Easytocare **101-102**
Santen **113**
SJJ Solutions **107**
Teva **4**
Trusetal **82**

Medic Clean Air

Build your own outpatient facility with Medic Clean Air


Since 1995, Medic Clean Air has been **developing and installing innovative air purification systems** for healthcare environments. Our compact technology makes it possible to create fully equipped **operating or treatment rooms** even within existing buildings.



From concept to completion: guiding you step by step to a safer environment

Design & consultancy
We develop a concept together that is tailored to the available space and takes into account the guidelines for extramural centers.

Compact technology
Air purification, controlled overpressure, and temperature control in one system.



Result
A sterile, comfortable, and energy-efficial space, ideal for extramural centers such as eye clinics and plastic surgery centers.

Validation & follow-up
Each project is validated and monitored in accordance with the Belgian standards and guidellines.

Fast installation
Minimal impact on existing infrastructure.

Together with the doctor, we have integrated a fully-fledged operating theatre into an existing practice, completely customized and built to the higest standards. ***- Medic Clean Air***

Would you like to build your own extramural center? Contact Medic Clean Air for a consultation.
Scan the QR code or visit our website www.mediccleanair.com

PREFACE

Dear Colleagues,

We are pleased to present INFO 143, a special edition dedicated to the upcoming Ophthalmologica Belgica Congress – **OB 2026, taking place from 25 to 27 November at SQUARE Brussels Convention Centre**.

Alongside our regular features and updates from the Belgian ophthalmological community, **this edition includes the full scientific programme of OB 2026**, offering an overview of the sessions, presentations and activities awaiting you in Brussels.

The annual OB Congress remains a key meeting point for Belgian ophthalmology, bringing together colleagues, residents, researchers and industry partners to exchange knowledge, explore new developments and strengthen professional connections. We warmly invite you to join us for three days of scientific exchange, inspiration and collegiality.

We are also delighted to announce that **AMICO 2027 will return as a LIVE event**! After previous virtual editions, we look forward to welcoming you in person on 20 March 2027 at SPARKS in Brussels, for a day dedicated to practical learning, interaction and professional exchange. More information will follow in the coming months.

We hope you enjoy reading this special edition of INFO and look forward to welcoming many of you to OB 2026 in Brussels!

Academia Ophthalmologica Belgica (AOB)

IN MEMORIAM

The Academia Ophthalmologica Belgica (AOB) was deeply saddened to learn of the passing of Daisy Godts, a highly respected member of the Belgian orthoptic and ophthalmological community.

For more than four decades, Daisy devoted herself to orthoptics and made an important and lasting contribution to the profession, both in Belgium and internationally.

Her commitment extended far beyond clinical practice. Throughout her career, she contributed to education, research and professional leadership, trained and mentored generations of orthoptists, and represented Belgian orthoptics on the international stage. Her involvement within the International Orthoptic Association and her commitment to international cooperation reflected the energy and dedication with which she approached her profession. Her humanitarian work also took her to different parts of the world, where she contributed not only to patient care but also to the training of local professionals.

In 2025, Daisy received the Stephenson Honorary Fellow Award, an international distinction recognising exceptional contributions to orthoptics in leadership, research, education and humanitarian service — a fitting recognition of a career dedicated to advancing her profession and sharing her knowledge with others.

Yet Daisy will be remembered for much more than her professional achievements.
For so many colleagues, she was a warm, enthusiastic and joyful presence — approachable, generous and deeply committed to the people around her. Her passion for orthoptics was unmistakable, but so too was the humanity with which she carried it. She brought people together and was a valued and much-loved colleague to many within Belgium and far beyond. Her passing represents a genuine loss to our community.
The AOB extends its heartfelt condolences to Daisy's family, friends and her many colleagues. Daisy Godts will be greatly missed, both as an exceptional professional and as a wonderful person.
With heartfelt condolences,

on behalf of the entire AOB / OB Board



Na een moedige maar oneerlijke strijd,
vol bewondering voor haar kracht en met intens verdriet,
nemen wij afscheid van

Daisy Godts

°9 maart 1961
†18 augustus 2026

Zij leeft verder in het hart van:

haar echtgenoot
Stef Deboutte

haar ouders
Alphred en Maria Godts - Terreur

haar kinderen en hun partners
Isabel Deboutte en Ruben Lojo Castillo
Maurane en Guillaume Deboutte - Mulliez

de families Deboutte en Godts.

CALL FOR APPLICATIONS AND NOMINATIONS

In 2027, the Champalimaud Foundation's 1 Million Euro Vision Award will be presented to **groups that contributed to the fight against blindness and visual impairment**, primarily in developing regions, **and/or have developed innovations or new technologies that impact on the quality of life of the blind and the visually impaired.**

The António Champalimaud Vision Award is the largest award in the fields of Vision and Ophthalmology and may be used in any way that furthers the outstanding contributions of the recipients.

We would like to invite you to submit an entry and/or help us identify any candidates you deem worthy from your organization or collaborative network. If you have nominated for the award or have been part of a candidate entry, we would be grateful if you send us an update. **Past award entries are automatically considered for 3 cycles of the award**, but candidates and/or nominators may send an update sheet and/or update the form, bibliography, and/or supporting letters accordingly.

The 2027 award is directed to groups actively involved in fighting blindness and visual impairment in the field, or that have developed innovations or new technologies for the blind and visually impaired with direct impact in developing countries. Candidates will be considered by a distinguished international jury for the quality and distinction of their work, their achievements, and the measurable impact of their pursuit, as well as the enduring amplifying effects of their activities. Here linked is our current announcement and the award entry form, which was carefully structured to make the nomination/application process easy and time-efficient. **The deadline for submissions is December 31st, 2026, with extension to early January arrivals (up to Friday, the 15th, 2027)** provided that candidates/nominators notify the Champalimaud Foundation of the submission. The laureates are contacted in June, and the Award is publicly announced in September 2027.

We will be happy to assist you, and/or any nominators or candidate groups you may indicate, at any time. Please do not hesitate to contact us directly to award@fchampalimaud.org or, for time-sensitive queries, to our numbers at +1 617 959 5277 (U.S.) or +351 210 480 200, ext. 4225 or 4237 (E.U.).

With very best regards,

André Valente
Director of the António Champalimaud Vision Award

Further information, as well as the linked forms and guidelines at:
https://www.fchampalimaud.org/vision-award

Champalimaud Foundation

Av. Brasília, 1400-038 Lisboa, Portugal

T (+1) 617 959 5277 (USA)
T (+351) 210 480 200 (Portugal, ext. 4225 or 4237)
Email: award@fchampalimaud.org

Rosario Brancato Retina Award



On behalf of Prof. Francesco Bandello and all the Award Committe Members, we are pleased to announce that the submission period for the *Rosario Brancato Retina Award* is now open for its sixt edition.
This prestigious award represents an important opportunity to recognize excellence in research and clinical practice in the field of retina studies.

For further information on the submission process and selection criteria, please visit the website

WWW.BRANCATOAWARD.EU

The prize, equal to **euro 30.000**, will be awarded during the **OCT & RETINA FORUM Congress** (Milano, 1st - 2nd April, 2027) and the winner will have the possibility to present a lecture.

WE INVITE YOU TO SUBMIT YOUR APPLICATION

by December 7th, 2026



do not miss the chance to take part in this important competition and join the list of Winners of the **ROSARIO BRANCATO RETINA AWARD!**

Winners of past editions:
Rajeev Muni - 2022, Enrico Borrelli - 2023
Maria Vittoria Cicinelli - 2024, Daniel Ting - 2025
Riccardo Sacconi - 2026

Discover more on the **BRANCATOAWARD.EU/ELIGIBILITY**

Geachte heer/mevrouw,

Time to Help Belgium is een Belgische humanitaire organisatie. Via onze cataractcampagne in Mali en Nepal ondersteunen wij, samen met Temps d'Aide Mali en Humanity Aid Nepal, patiënten die onvoldoende toegang hebben tot noodzakelijke oogzorg.



Cataractcampagne

Hoe verloopt het project?

Samen met onze lokale partners worden patiënten met een duidelijke medische en sociale nood geïdentificeerd, medisch beoordeeld, geopereerd en lokaal opgevolgd. De kostprijs van één cataractoperatie binnen dit project bedraagt €120.

Hoe kan uw organisatie helpen?

Door onze affiche of video zichtbaar te maken, de campagne te delen via uw communicatiekanalen, één of meerdere operaties te sponsoren, of via medische, materiële of netwerkondersteuning.

Campagnepagina:

timetohelp.be/projecten/cataract-operaties

Video NL:

https://youtu.be/JrSkQVOaHFI

Madame, Monsieur,

Time to Help Belgium est une organisation humanitaire belge. À travers notre campagne consacrée à la cataracte au Mali et au Népal, nous soutenons, avec Temps d'Aide Mali et Humanity Aid Nepal, des patients qui n'ont pas suffisamment accès aux soins ophtalmologiques nécessaires.



www.timetohelp.be

Comment fonctionne le projet ?
Avec nos partenaires locaux, les patients présentant un besoin médical et social réel sont identifiés, évalués médicalement, opérés et suivis localement. Le coût d'une opération dans le cadre du projet est de 120 €.

Comment votre organisation peut-elle contribuer ?
En rendant visible notre affiche ou notre vidéo, en relayant la campagne via vos canaux de communication, en finançant une ou plusieurs opérations ou en apportant un soutien médical, matériel ou de réseau.

Page de la campagne:
timetohelp.be/projecten/cataract-operaties
Vidéo FR:
https://youtu.be/uz1V4mi0eMA

ENSEIGNEMENT POST-UNIVERSITAIRE D'OPHTALMOLOGIE 2026-2027

Conférences organisées par le Service d'Ophtalmologie de l'Université de Liège

Début des exposes: 20 heures

Mardi 8 décembre 2026
Les limites de l'IA*
Dr C.-J. Mehanna
(Centre Hospitalier Intercommunal Créteil)

Mardi 12 janvier 2027
Cas inhabituels de la clinique ophtalmologique du CHR et du CHU
Dr F. Korzewski (CHR Citadelle) - Pr J.-M. Rakic (CHU Liège)

Mardi 16 février 2027
Diagnostic et prise en charge du mélanome uvéal au CHU de Liège
Dr S. Kairis (CHU-Institut Curie Paris)

Mardi 16 mars 2027
Le traitement médico-chirurgical des patients « qui n'ont rien »
Dr A.-C. Chapelle (CHU Liège) - Dr V. Paris (CHU Liège)

Mardi 13 avril 2027
Influences des œstrogènes et de leurs inhibiteurs en ophtalmologie
Dr. A. Radermecker - CHU Liège

Mardi 25 mai 2027
Kératite neurotrophique un défi thérapeutique entre cicatrisation et innovation
Dr J. Crommen (CHU Liège)

Mardi 29 juin 2027
Actualités dans la chirurgie de la myopie
Dr N. Rakic (CHU Liège, CHU Rouen)

***Accréditation éthique et économie demandée**



Lieu: Château de Colonster - Allée des Erables - 4000 Liège

Accès au Château de Colonster

Venant de BXL ou de Namur, prendre la E25 direction Luxembourg, sortie 40 (Embourg), l'entrée du château se situe sur la première route à droite dans la montée vers le Sart-Tilman.

ManaMa
courses

overview program 2026-2027

2026	December 12, 2026	Neuro-Ophthalmology	ULiège
2027	January 30, 2027	Retina	ULB Erasme
2027	June 12, 2027	Glaucoma	UZ Leuven

www.ophthalmologia.be

ManaMa

SAVE THE DATE

Master after Master course organized by the Collegium Ophthalmologicum Belgica

Neuro-Ophthalmology

Saturday, December 12, 2026 - 08:45 - 16:30


Organiser:
Organised by ULiège - Dr Jean-Marie Rakic, Anne-Catherine Chapelle, Cécile Andris

Venue:
Faculté de Médecine - next to the University Hospital CHU Sart-Tilman
Building B35a - Amphithéatre ROSKAM
Access via de large cobblestone courtyard, entrance on the right-hand side of (opposite the hospital entrance).

Programme: See page 2

Directions and Parking:
Easiest access by car: E25 exit 40
Address in Waze: P109 CHU (parking)

Easiest access by public transport:
Arrive by train at Liège-Guillemins.
Take the bus line B2 direction CHU
(20min drive, stop in front of CHU)



--- REGISTRATION IS REQUIRED ! ---

Registration:
Visit the website
www.ophthalmologia.be
login and go to
"My Payments"
Select ***"ManaMa 2026/4"***
>> Registration is free for Residents (but still required)

Accreditation:
Accreditation is requested.

>> *To receive certificate of attendance / accreditation you need to have registered for the event AND have scanned QR code onsite - Thank you!*

QR code - Attendance tracking:

A poster with a QR code will be available on-site for registering your attendance to the course. To ensure proper tracking, the QR code must be scanned twice. At the beginning and the end of the programme.

This process helps us maintain accurate attendance records.

Neuro-Ophthalmology

08:45 Welcome and Registration (Cécile Andris & Anne-Catherine Chapelle)

Part 1: Neuro-Ophthalmic Anatomy and Imaging

09:00 Neuro-Ophthalmic Anatomy Through MRI: A Clinician's Guide
Cédric Balez (ULB)
09:20 Emerging Imaging Techniques for the Optic Nerve, Advanced Visual Field Testing, and the Role of AI in Neuro-Ophthalmology
Célia Kouam (ULiège)

Part 2: Optic Neuropathies and Differential Diagnosis

09:40 Inflammatory Optic Neuropathies: What's New?
Anne-Catherine Chapelle (ULiège)
10:00 Non-Arteritic Ischemic Optic Neuropathy (NAION): Recent Advances
Anne-Catherine Chapelle (ULiège)

10:20 ***Coffee Break***

11:00 Idiopathic Intracranial Hypertension:
Current Management Strategies (CSF Diversion, Venous Sinus Stenting, and Semaglutide)
Mohammed Alsaddi (UZA)
11:20 The Chiasm Uncovered: A Practical Approach to Chiasmal Disease
Tom Buelens (ULB)
11:40 Retinal Pitfalls for the Neuro-Ophthalmologist
Alexandra Kozyreff (UCL)
12:00 Tumors Every Neuro-Ophthalmologist Should Know:
Orbital Tumors, Optic Nerve Tumors, and Paraneoplastic Disorders
Solène Kairis (ULiège)

12:20 ***Lunch***

Part 3: Diplopia, Pupils, and Nystagmus

13:30 Approach to the Patient with Diplopia: Critical Diagnoses Not to Miss
Antonella Boschi (UCL)
13:50 Supranuclear Eye Movement Disorders: A Practical Guide to Recognition and Diagnosis
Catherine Cassiman (KU Leuven)
14:10 Thyroid Eye Disease: Latest EUGOGO Guidelines, Novel Therapies, and Ongoing Clinical Trials
Cécile Andris (ULiège)
14:30 Anisocoria: Essential Diagnoses Not to Miss
Michel Van Lint (VUB)
14:50 Practical Management of Nystagmus
Alionka Bostan (ULB)

15:10 ***Coffee Break***

Part 4: Beyond the Optic Nerve: Genetics, Functional Disorders, and Pain

15:30 Neuro-Ophthalmic Genetics: Present and Future Applications
Julie De Zaeytijd (UGent)
15:50 Functional Visual Disorders: Diagnosis and Management
Cécile Andris (ULiège)
16:10 Headache and Facial Pain: A Neuro-Ophthalmic Perspective
Sophie Lemmens (KU Leuven)

16 :30 ***End of the Meeting***

Annual Meeting in Clinical Ophthalmology

AMICO 2027

returns LIVE in Brussels

Saturday
20 March 2027

Sparks, Brussels








SAVE THE DATE

PARTICIPANT INVITATION

- CLINICAL CASE DISCUSSIONS
- PRACTICAL SESSIONS
- EXPERT DEBATES
- NETWORKING & EXCHANGE

A RENEWED LIVE MEETING. A FRESH CLINICAL FOCUS.
NEW OPPORTUNITIES TO CONNECT.


WCPOS VI
CANCUN 2027
WSPOS
World Society of Paediatric Ophthalmology and Strabismus
in conjunction with
Sopla
WCPOS VI
WORLD CONGRESS OF PAEDIATRIC OPHTHALMOLOGY AND STRABISMUS
May 13 – 15, 2027
Cancun, Mexico
SAVE THE DATE
www.wspos.org



18th EuCornea Congress

BUDAPEST

14-16 May, 2027

Crowne Plaza Budapest

DATES TO NOTE

Abstract Submission - Opening October 2026

Registration - Opening November 2026

www.eucornea.org

International Ocular Inflammation Society

IOIS CONGRESS 2027

7th-10th July

FUKUOKA
JAPAN

World's Largest Assembly on Ocular Inflammation !



SAVE THE DATE

The 19th International Ocular Inflammation Society Congress a joint meeting with the Japanese Ocular Inflammation Society for the Study of Ocular Inflammations and Infections.

www.iois.info

PREMIERE !

VIVOS

A NEW APPROACH TO PHACO



CORE:
Cataract Surgery
with Power and Control.

VIVOS CORE®

NOVA:
Phaco, Vitrectomy,
Endoillumination.
Flow and Precision.

VIVOS NOVA®

NOVA+:
The Full Configuration for the
Anterior and Posterior Segment.
Including Laser.

VIVOS NOVA+

Geuder®
Germany

vivos.de/en

Your distributor:

ARSEUS MEDICAL GROUP

Van Hopplynus Ophtalm

OPHTALMO

www.vho.be - arseusmedicalgroup.com

VH26012

INFO

What's Happening ?
Congresses - meetings - courses - ...

CALENDAR

CONGRESS CALENDAR

25-27 November 2026 — **OB 2026**
SQUARE, Brussels Meeting Center
https://www.ophthalmologia.be/page.php?edi_id=2035

08 December 2026 — **Enseignement post-universitaire d'ophtalmologie**
Château de Colonster: Allée des Erables, 4000 Liège
Les limites de l'IA*
Dr C.-J. Mehanna
(Centre Hospitalier Intercommunal Créteil)
Conférences organisées par le Service d'Ophtalmologie de l'Université de Liège
Début des exposés : 20 heures

12 January 2027 — **Enseignement post-universitaire d'ophtalmologie**
Château de Colonster: Allée des Erables, 4000 Liège
Cas inhabituels de la clinique ophtalmologique du CHR et du CHU
Dr F. Korzewski (CHR Citadelle)
Pr J.-M. Rakic (CHU Liège)
Conférences organisées par le Service d'Ophtalmologie de l'Université de Liège
Début des exposés : 20 heures

28 January 2027 — **Soirée DMLA 2027**
Hôtel Mercure, 157 avenue de la Marne, 59700 Marcq-en-Barœul (France)
https://forms.cloud.microsoft/r/yVF9ze4vXV
thomas@desmettre.org
Programme :
DMLA précoce et intermédiaire : une place pour la photobiomodulation ? - *Pr Thomas Desmettre (Lille)*
DMLA néovasculaire : impact des fluides intra- et sous-rétiniens selon les types de néovascularisation - *Pr Thibaud Mathis (Lyon)*
Réunion organisée par l'ASO, avec le soutien des Laboratoires Roche.
Programme et inscription :
https://forms.cloud.microsoft/r/yVF9ze4vXV

16 February 2027 — **Enseignement post-universitaire d'ophtalmologie**
Château de Colonster: Allée des Erables, 4000 Liège
Diagnostic et prise en charge du mélanome uvéal au CHU de Liège
Dr S. Kairis (CHU-Institut Curie Paris)
Conférences organisées par le Service d'Ophtalmologie de l'Université de Liège
Début des exposés : 20 heures

16 March 2027 — **Enseignement post-universitaire d'ophtalmologie**
Château de Colonster: Allée des Erables, 4000 Liège
Le traitement médico-chirurgical des patients « qui n'ont rien »
Dr A.-C. Chapelle (CHU Liège)
Dr V. Paris (CHU Liège)
Conférences organisées par le Service d'Ophtalmologie de l'Université de Liège
Début des exposés : 20 heures

20 March 2027 — **AMICO 2027**
Sparks, Brussels
AMICO – Annual Meeting in Clinical Ophthalmology returns as a live meeting in 2027.
Join colleagues from across the Belgian ophthalmology community on 20 March 2027 at Sparks in Brussels for a meeting dedicated to clinical ophthalmology and everyday practice.
AMICO 2027 will bring together the different ophthalmological subspecialties in one joint meeting, with a varied programme combining scientific presentations, case-based discussions and interactive workshop-style sessions, with practical or hands-on elements where appropriate.
A valuable opportunity to update your clinical knowledge, exchange with colleagues and experts, and connect across specialties in one dynamic spring meeting.

13 April 2027 — **Enseignement post-universitaire d'ophtalmologie**
Château de Colonster: Allée des Erables, 4000 Liège
Influences des œstrogènes et de leurs inhibiteurs en ophtalmologie
Dr J. Crommen (CHU Liège)
Conférences organisées par le Service d'Ophtalmologie de l'Université de Liège
Début des exposés : 20 heures

2-6 May 2027 — **ARVO 2027**
San Diego, California
https://www.arvo.org/annual-meeting

13-15 May 2027 — **WCPOS VI**
Cancun, Mexico
www.wspos.org
World Congress of Paediatric Ophthalmology and strabismus

14-16 May 2027 — **EuCornea 2027**
Budapest, Hungary

25 May 2027 — **Enseignement post-universitaire d'ophtalmologie**
Château de Colonster: Allée des Erables, 4000 Liège
DMEK/ Ultrathin DSEAK: résultats de l'étude Best Cornea
Pr B. Duchesne (CHU Liège)
Conférences organisées par le Service d'Ophtalmologie de l'Université de Liège
Début des exposés : 20 heures

18-20 June 2027 — **SOE 2027**
Athens, Greece
https://soe2027.soevision.org/
secretariat@soevision.org
A Multi-Speciality Congress, for the general & specialist ophthalmologist

29 June 2027 — **Enseignement post-universitaire d'ophtalmologie**
Château de Colonster: Allée des Erables, 4000 Liège
Actualités dans la chirurgie de la myopie
Dr N. Rakic (CHU Liège, CHU Rouen)
Conférences organisées par le Service d'Ophtalmologie de l'Université de Liège
Début des exposés : 20 heures

7-10 July 2027 — **IOIS 2027**
Fukuoka, Japan
https://www.iois.info/page.php?edi_id=1697
International Ocular Inflammation Society.
SAVE THE DATE for the World's Largest Assembly on Ocular Inflammation!

24-26 November 2027 — **OB 2027**
SQUARE, Brussels Meeting Center
https://www.ophthalmologia.be/page.php?edi_id=2035



EEN ANDERE KIJK OP HET LEVEN

UNE AUTRE FAÇON DE VOIR LA VIE

Op weg naar inclusie van blinde en slechtziende personen

Cap sur l'inclusion des personnes aveugles et malvoyantes

brailleliga vzw
ligue braille asbl

De nieuwe referentiegids over de visuele handicap.

Scan deze QR-code om jouw exemplaar te ontvangen

Le nouveau guide de référence sur la déficience visuelle.

Demandez votre exemplaire, scannez ce QR code

INFO

KLEINE AANKONDIGINGEN

PETITES ANNONCES

11/11/2026

Focus Oogkliniek breidt uit – versterk ons team in Hove

Focus Oogkliniek breidt haar activiteiten uit. Naast onze recent gerenoveerde en moderne praktijk in Wilrijk, openen we in september 2027 een volledig nieuwe vestiging in Hove, die als satellietpraktijk zal functioneren binnen de bestaande structuur van Focus Oogkliniek Wilrijk.
Voor deze nieuwe locatie zijn we op zoek naar extra collega-oogartsen (tot 2 FTE) die ons team willen versterken.
Onze nieuwe praktijk in Hove wordt uitgerust met moderne infrastructuur en hoogtechnologische apparatuur. Alles is voorzien om consultaties efficiënt, comfortabel en op een hoog medisch niveau te laten verlopen.

Je kan rekenen op de ondersteuning van een ervaren en multidisciplinair team, bestaande uit een medisch secretariaat, verpleegkundigen, een planningsmanager, optometristen en orthoptisten.
Infrastructuur en materiaal:
In Hove:
- 4 consultatiekamers, voor 2 oogartsen + 2 optometristes. volledig uitgerust met NIDEK refractieketens, HAAG STREIT units en spleetlampen, ...
- Heidelberg OCT
- Quantel Argonlaser
- Nidek YAG-laser
- Perivision gezichtsveldonderzoek
- Quantel A- en B-echografie
- iCare DRSplus funduscamera
- Poliklinische operatiekamer voor oculoplastische ingrepen, intravitreale injecties en andere ambulante behandelingen.

In Wilrijk:
Als onderdeel van Focus Oogkliniek krijg je ook toegang tot de uitgebreide infrastructuur van onze hoofdvestiging in Wilrijk:
- Fluorescentieangiografie en OCTs van Heidelberg.
- SLT
- Octopus en HFA gezichtsveldonderzoeken.
- Preoperatieve diagnostiek met Nidek-speculaire microscopie, biometrie en Heidelberg Anterion.
- Een moderne behandelkamer en een volledig nieuw operatiekwartier voor intraoculaire en ooglidchirurgie, uitgerust met onder andere Zeiss Lumera I, Alcon Centurion, ERBE VIO 300 cauter, en een volledige Melag-sterilisatieketen.

We staan open voor verschillende profielen en interesses. In het bijzonder willen we ons team verder versterken met oogartsen met een bijzondere interesse in:
- Glaucoom en glaucoomchirurgie
- Medische retina
- Algemene oogheelkunde

Wat bieden we?
- Tot 2 FTE beschikbaar vanaf september 2027.
- Een volledig nieuwe, moderne praktijkomgeving.
- Ondersteuning door een uitgebreid multidisciplinair team.
- Toegang tot de volledige infrastructuur van Focus Oogkliniek Wilrijk.
- Gegarandeerde operatietijd voor chirurgische oogartsen met gunstige verloning.

Interesse om kennis te maken of vrijblijvend de mogelijkheden te bespreken? Neem gerust contact met ons op.
Joachim Riems 0470 45 29 59 - dr.riems@gmail.com

10/11/2026

Vacature oogarts (1 dag/week)

Voor mijn solo-praktijk in Beernem ben ik op zoek naar een enthousiaste collega-oogarts om de praktijk 1 dag per week te versterken, dit bij voorkeur op donderdag (bespreekbaar).
Wegens aanhoudende vraag en om de continuïteit en kwaliteit van de patiëntenzorg te waarborgen, zoek ik een aangename collega die zelfstandig wil werken in een moderne, goed uitgeruste praktijkomgeving.
Interesse? Neem gerust contact op voor meer info !
Veerle Vanlerberghe 0477/30 25 62

19/10/2026

Moderne, volledig uitgeruste oogheelkundige praktijk over te nemen in Landen

Wegens stopzetting van de activiteiten wordt een volledig uitgeruste oogheelkundige praktijk in Landen ter overname aangeboden. De praktijk beschikt over moderne medische apparatuur, up-to-date software en hardware (4 computers) en een functionele, comfortabele inrichting, waardoor ze een uitstekende basis vormt voor de verdere uitbouw of opstart van een eigen praktijk.
Volledig uitgerust met moderne apparatuur:
- IOL Master
- ECT
- OCT
- YAG-laser
- Humphrey-perimeter
- Pneumotonometer
- Autorefractor
- Diverse andere onderzoeks- en meettoestellen

De gelijkvloerse praktijk omvat:
- Twee volledig uitgeruste onderzoeksruimtes, elk voorzien van een complete unit met spleetlamp, automatische phoropter en bijhorende apparatuur.
- Een aparte technische ruimte met alle nodige meettoestellen.
- Een lokaal voor kleine ingrepen, uitgerust met een Ellman-toestel en een in hoogte verstelbare onderzoekszetel.
- Een secretariaatsruimte en een verzorgde ontvangstbalie.
- Een ruime wachtzaal voor patiënten.
- Een aparte keuken met grote eettafel, ideaal voor pauzes en overleg.
- Een zuidgericht buitenterras, dat zorgt voor extra comfort en aangename ontspanningsmogelijkheden.

Comfortabele ligging en vlotte bereikbaarheid
Het pand is volledig gerenoveerd in 2012 en bevindt zich op een goede locatie in Landen. De praktijk is volledig gelijkvloers, wat zorgt voor een praktische en toegankelijke werkomgeving.
Bovendien beschikt het pand over een privéparking en ruime parkeermogelijkheden voor patiënten, een belangrijke troef voor een vlotte bereikbaarheid.
Interesse of meer informatie?
Neem vrijblijvend contact op voor meer informatie via: annick.morien@telenet.be

18/10/2026

Collega gezocht: zwangerschapsvervanging en/of permanente aanbieding

Ons team breidt uit!
Wat kunnen wij jou bieden?
Een nieuwe groepspraktijk met 3 artsen, een optometrist, 2 orthoptisten, 2 verpleegkundigen en medisch secretariaat, met volledige technische ondersteuning en administratieve ontzorging. Alle high end toestellen zijn aanwezig om uw consultatie/ behandeling vlot te laten verlopen. Extramuraal operatiezaal aanwezig.
Wat zoeken wij?
Een enthousiaste collega die ons team kan versterken. Voltijds/deeltijds is bespreekbaar. Subspecialisatie is een pluspunt, maar geen must. Chirurgie is mogelijk.
Gezien één van de artsen in zwangerschapsverlof is van feb-mei is tijdelijke invulling ook mogelijk indien gewenst.
Regio?
Lokeren, 30 min van Gent/Antwerpen
Interesse of vragen?
Laat ons kennismaken!
Annelies Goegebuer: 0478/ 58 13 74
Justine Vandeputte: 0479/ 51 30 52
E-mail justine_vandeputte@hotmail.com

5/10/2026

Fellowship Cataractchirurgie 2027–2028 | New Vision

Je hebt je opleiding oftalmologie (bijna) achter de rug en wil cataractchirurgie echt onder de knie krijgen? Het New Vision Fellowship Cataract geeft je van november 2027 tot november 2028 een jaar lang gesuperviseerde chirurgische ervaring binnen een gespecialiseerde praktijk.
Wat je krijgt:
Een traject op jouw niveau. Je start in een basistraject of een ervaringstraject, afhankelijk van wat je al kan. Zo bouw je stap voor stap op, van je eerste gesuperviseerde ingrepen tot zelfstandig opereren.

Lees verder >>

Persoonlijke supervisie door Dr. Patricia Casaer en Dr. Frédéric Smeets, met directe feedback in de operatiezaal.
Het volledige cataracttraject. Niet alleen de ingreep zelf, maar ook preoperatieve work-up, biometrie en lenskeuze, patiëntcounseling en postoperatieve opvolging.
Voor wie?:
Recent afgestudeerde oogartsen die zich willen verdiepen in cataractchirurgie.
Voorkeur voor een voltijdse activiteit, met een minimum van 4/5de aanwezigheid.
Solliciteren vóór 20 december 2026 via mail naar oogpraktijk@newvision.be met:
- je curriculum vitae
- een aanbevelingsbrief
- een korte motivatie
Daarna nodigen we je graag uit voor een kennismakingsgesprek.
Meer weten? Vraag onze informatiebrochure aan via oogpraktijk@newvision.be, of stel je vragen gewoon rechtstreeks. We horen graag van je.
Tel.014 49 06 16

5/10/2026

Vacature Oogarts – New Vision Laakdal / Westerlo

New Vision Oogpraktijk is een multidisciplinaire oogpraktijk met verschillende vestigingen. Voor de verdere uitbouw van ons team zijn wij steeds op zoek naar enthousiaste collega-oogartsen die mee hun schouders willen zetten onder kwalitatieve, patiëntgerichte oogzorg te Laakdal en Westerlo.

Wat wij bieden:
- Een dynamische, multidisciplinaire groepspraktijk met ondersteuning van ervaren medewerkers in administratie, optometrie, verpleegkunde en coördinatie.
- Ruimte om jezelf te ontwikkelen en je eigen traject uit te bouwen – zowel als arts, collega én persoon.
- Flexibele samenwerkingsformules.
- State-of-the-art uitgeruste locaties met een ruim aanbod aan extramurale chirurgische en andere behandelingen.
- Kansen om door te groeien en te verdiepen in een subspecialisatie.
- Een inspirerende werkomgeving met kruisbestuiving tussen verschillende disciplines.

Wat wij belangrijk vinden:
Gepersonaliseerde, hoogwaardige oogzorg brengen waarin de patiëntbeleving centraal staat. Jouw visie en creatieve bijdrage om onze zorgtrajecten verder te optimaliseren zijn voor ons een echte meerwaarde.
Wie we zoeken:
Gemotiveerde, flexibele oogartsen die wil groeien. Iemand die waarde wil toevoegen aan ons team, onze patiënten en de samenwerking met andere zorgverstrekkers.
Interesse? We maken graag kennis met jou!
Stuur een mailtje naar oogpraktijk@newvision.be t.a.v Patricia Casaer of Frédéric Smeets
of bel ons op 014 49 06 16.

4/10/2026

Vacancy: Refractive Surgery Fellowship

Dear colleague or resident in training,
We are hereby reopening a vacancy for the fellowship in anterior segment and refractive surgery, running from 1 October 2027 to 30 September 2028.
This is a full-time (9/10) 12-month fellowship, to be carried out both in a hospital setting and on an outpatient basis.
Candidates will have the opportunity to actively participate in consultations in refractive and general ophthalmology, and to perform surgery under supervision and/or independently.
Cataract surgery using the Catalys laser, with monofocal, multifocal and EDOF lenses, ICL, femto-LASIK, SMILE and Presbyond, forms part of the weekly routine.
You will also be taught the basics of eyelid surgery.
The aim of the fellowship is to enable you to achieve a high degree of autonomy in this subspeciality by the end of the programme.
A pleasant manner and a professional attitude towards colleagues and staff are considered essential.
Please submit your application by email by 15 December 2026.
m. 0497170360 - e. frankjr@goes.be

18/9/2026

Vacature optometrist regio Kortenberg

Oogcentrum Kortenberg is op zoek naar een gemotiveerde optometrist(e).
Ons centrum is gelegen pal tussen Leuven en Brussel en is goed uitgerust met de meest recente toestellen.
Ben jij geïnteresseerd om deel uit te maken van ons dynamisch team?
Aarzel dan niet om contact met ons op te nemen via evadiltoer@oogcentrumkortenberg.be of 0475/96.03.26. Hopelijk tot snel

8/9/2026

Oogarts privépraktijk Mol

Vacature Oogarts
Bouw mee aan je toekomst in een moderne Oogkliniek

Oog Centrum Kempen is een gevestigde en groeiende oogartsenpraktijk onder leiding van dr. Pieter Raus, met meer dan 25 jaar ervaring in de oogheelkunde. Om ons team verder te versterken, zijn we op zoek naar een enthousiaste en patiëntgerichte oogarts.

Bij ons hoef je geen praktijk vanaf nul op te bouwen. Je krijgt vanaf de start een bestaande patiëntenpopulatie en een goed gevulde agenda, terwijl je tegelijk alle ruimte krijgt om je eigen professionele interesses uit te bouwen.

Waarom kiezen voor Oog Centrum Kempen?
Je komt terecht in een moderne groepspraktijk waar kwaliteit, samenwerking en innovatie centraal staan.

Wij bieden je:
Een onmiddellijke patiënteninstroom en goed gevulde agenda.
Een volledig uitgeruste en moderne praktijk met de nieuwste diagnostische apparatuur.
Een eigen operatiezaal, met ruimte om je chirurgische vaardigheden verder te ontwikkelen. Dit kan, indien gewenst, ook onder begeleiding.
Mogelijkheden omvatten onder meer cataractchirurgie, ooglasercorrecties, blepharoplastie en anti-VEGF-behandelingen.
Een ervaren en dynamisch team van verpleegkundigen, optometristen en secretariaatsmedewerkers, zodat de administratieve belasting minimaal blijft en jij je maximaal kunt concentreren op je patiënten.
Volledige vrijheid om je eigen interesses en subspecialisatie verder uit te bouwen.
Zowel 1 dag in de week of meerder dagen per week zijn mogelijk, afhankelijk van het subdomein.
Een uitstekende work-lifebalans, met de mogelijkheid om jaarlijks tot 8 weken vakantie op te nemen.
Een aantrekkelijke en bovengemiddelde verloning.
Een duidelijk toekomstperspectief binnen een groeiende praktijk.
Wie zoeken wij?
Wij zijn op zoek naar een enthousiaste, betrokken en patiëntgerichte oogarts die graag deel wil uitmaken van een collegiaal team.

Een bijzondere interesse in één of meerdere van onderstaande domeinen is een meerwaarde:
specialisatie achterste oogsegment (diagnostisch en behandelingen, Anti-VEGF...)
OF
cataractchirurgie
refractieve chirurgie
OF
ooglidchirurgie en
esthetische behandelingen van de oogregio, zoals blepharoplastie en botulinetoxine

Ook pas afgestudeerde oogartsen zijn van harte welkom. Je kunt rekenen op een omgeving waarin samenwerking, overleg en professionele ontwikkeling vanzelfsprekend zijn.

Bij Oog Centrum Kempen combineren we hoogwaardige oogheelkundige zorg met een persoonlijke aanpak. We investeren voortdurend in moderne infrastructuur, nieuwe technieken en kwaliteitsvolle patiëntenzorg en beschikken over een eigen operatiezaal (refractieve laser en phaco).

Interesse? Dan maken we graag kennis met je.

Meer informatie: www.oogcentrumkempen.be
Contact: Dr. Pieter Raus - eindverantwoordelijke
0475 25 63 50 - pieterraus@hotmail.com

6/9/2026

Orthoptist / Optometrist wanted – Antwerp

Oogcentrum Baron Joostensstraat in Antwerp is looking for an orthoptist/optometrist, for a position of 8h/week.
Collaboration possible as an employee or as self-employed.
Start possible from October 2026.
Interested? Contact Dr. Sarah Hershko via hershkosarah@gmail.com

Lees verder >>

1/9/2026

Orthoptist(e) – AZ Groeninge

Ben jij orthoptist(e) en zoek je een uitdagende deeltijdse functie die perfect combineerbaar is met een andere job of een zelfstandige activiteit?
Voor onze dienst in AZ Groeninge zoek ik een enthousiaste collega waarmee ik samen de strabologische en pediatrische raadpleging verder kan uitbouwen. Je krijgt veel autonomie, werkt met moderne onderzoeksapparatuur en komt in contact met een gevarieerde patiëntenpopulatie.

Over ons
Je komt terecht in een dynamische werkomgeving en professioneel georganiseerde dienst. Ons team bestaat uit 7 oogartsen, 1 orthoptiste en 3 medisch secretaressen.

Jouw uitdaging
In nauwe samenwerking staan we in voor de strabologische en pediatrische consultaties met een gevarieerde pathologie.
Je staat onder andere in voor:
• amblyopie controles
• onderzoek en behandeling van patiënten met diplopie
• preoperatieve onderzoeken ter voorbereiding van strabismechirurgie
Afhankelijk van jouw interesses en expertise kan het takenpakket in de toekomst uitgebreid worden.

Wie zoeken wij?
• Je bent afgestudeerd als orthoptist(e).
• Je werkt nauwkeurig, patiëntgericht en zelfstandig.
• Je bent een enthousiaste teamspeler die graag meedenkt over kwaliteitsvolle zorg.

Wat bieden wij jou?
• Een deeltijdse functie in een dynamische en uitdagende werkomgeving (1 dag per week bij voorkeur donderdag of vrijdag – invulling bespreekbaar).
• Samenwerking in loondienst of op zelfstandige basis.
• Een volledig uitgeruste eigen consultatieruimte met synoptofoor, Hess, Maddox en bijkomend orthoptisch materiaal.
• Een gevarieerde patiëntenpopulatie & pathologie.
• Een goed georganiseerde en professionele werkomgeving.
• Opstart voorzien vanaf januari 2027 (eerder starten is bespreekbaar).

Interesse?
Stuur vrijblijvend een mailtje of neem contact op voor een kennismakingsgesprek.
Dr. Laure Dequeker
dequeker.laure@gmail.com

31/8/2026

Oftalmoloog gezocht | Tessenderlo

Wij zoeken een oftalmoloog voor onze vestiging in Tessenderlo.
De huidige oftalmologe wilt haar agenda verder afbouwen in aanloop naar haar pensioen. De eerste vrije afspraak in onze agenda is pas beschikbaar in januari 2027 op dit moment. Werken bij Practimed is werken in een warme, professionele en bijzonder goed draaiende polikliniek met meer dan 300 verwijzers.

Meer informatie:
Practimed BV is een organisatie opgericht door huisartsen voor huisartsen.
Ze omvat 3 poliklinieken op drie locaties in Limburg (Tessenderlo, Bree en Maasmechelen) en een laboratorium in Tessenderlo. Bij Practimed werken 175 collega's in dienstverband en 150 arts-specialisten, die zich elke dag met hart en ziel inzetten voor de zorg van anderen.

Wie zoeken wij?
Wij zoeken een oftalmoloog die consultaties wil doen in onze polikliniek in Tessenderlo omwille van een bijzonder lange wachtlijst. Ingrepen en operaties kunnen uiteraard meegenomen worden naar de eigen praktijk of het ziekenhuis.

Beschikbare momenten
• Maandag-, dinsdag-, woensdag- en vrijdagnamiddag
• Donderdag: hele dag
• Verschuivingen zijn mogelijk, dus bezetting is bespreekbaar.

Waarom kiezen voor Practimed?
• Aangename, moderne werkomgeving
• Filevrije locatie
• Professionele verpleegkundige ondersteuning
• Alle noodzakelijke toestellen aanwezig:
  - Autokerato-refractometer
  - Field analyzer
  - OCT
  - Tonometer
  - Spleetlamp
  - Auto-phoropter
  - Eyefile beschikbaar

INTERESSE
Mocht u geïnteresseerd zijn om het gesprek aan te gaan of om onze faciliteit te bezoeken, neem dan gerust contact op met Stefanie Gielen, directeur bedrijfsbeheer:
E-MAIL: stefanie.gielen@practimed.be
GSM: 0473/34 44 03
ADRES: Groenstraat 27, 3980 Tessenderlo-Ham

22/8/2026

Matériel de consultation et chirurgies

a vendre matériel de consultation (ophtalmoscope, tonometre à air , pachymetre etc)
+ boites de chirurgie (cataracte et strabisme)
Contacter le 0475/36.59.49 ou jeanpierredelaey@gmail.fr

10/8/2026

Fellowship cataract and ant segment eye surgery
Fellowship in cataract surgery 1y
Tel. 0478/56.55.29
frank.kesteloot@oogartsencentrum.be

3/6/2026

Collega oogarts gezocht voor praktijk Menen

Wij zijn op zoek naar een gemotiveerde oogarts om ons team te versterken. Op heden actief met 3 oogartsen, allen verbonden aan AZ Delta Roeselare. Opstart praktijk is voorzien in september 2026.
Modern uitgeruste praktijk met ondersteuning van een medisch secretariaat.
Uitrusting van de praktijk:
• Gezichtsveldonderzoek
• OCT
• Biometrie
• Lokaal voor kleine ingrepen.
Operaties kunnen doorgaan in AZ Delta.
Wij bieden:
• Flexibele samenwerkingsvorm (voltijds/deeltijds bespreekbaar)
• Goed georganiseerde praktijk met efficiënte ondersteuning
• Moderne apparatuur en comfortabel ingerichte consultatieruimtes
• Veel groeipotentieel te verwachten cfr regio met groot drainage gebied.
Profiel:
• Erkend oogarts (of laatste jaar opleiding)
• Teamgericht, patiëntvriendelijk en gemotiveerd.
Interesse om u bij ons team aan te sluiten? Neem vrijblijvend contact op voor meer informatie of een verkennend gesprek.

Tel. 0479/02.64.98
julie.imschoot@azdelta.be

OB

25 NOV 26 NOV 27 NOV 2026

LIVE IN SQUARE

OPHTHALMOLOGICA BELGICA

OB 2026
OPHTHALMOLOGICA BELGICA

Academia Ophthalmologica Belgica, AOB vzw-asbl

Meet the OB 2026 Organizing Committee



Werner Dirven
OB President



Frank Goes Jr
Programme Director



Nacima Kisma
Treasurer



Karel Van Keer
Wetlab



Jozef Depla
Wetlabs +
Free Papers & Posters



Nathalie Collignon
ICC



Maëlle Coutel
Social Event

Voorwoord



Geachte collega's,

Er zijn dagen waarop een vakgebied zich laat zien op zijn best: wanneer verschillende generaties oogartsen samenkomen, kennis delen en elkaar herinneren aan waarom ze ooit voor dit prachtige vak kozen. Van **woensdag 25 tot en met vrijdag 27 november 2026** zijn dat precies die dagen. Met groot enthousiasme nodigen wij u uit voor de 33ste editie van Ophtalmologica Belgica, OB 2026, opnieuw op de vertrouwde locatie **Square**, in het hart van Brussel, terwijl de stad zich langzaam in feestelijk licht hult.

Wat geen scherm kan geven
Informatie is overal beschikbaar, en vergaderen doen we intussen vanuit de zetel. Maar inspiratie ontstaat zelden alleen achter een beeldscherm. Ze groeit in de gang tussen twee sessies, in een onverwachte gedachtewisseling, in het weerzien van een oude vriend. En laten we eerlijk zijn: geen enkele virtuele koffiepauze haalt het bij de echte.

Een programma dat uitdaagt en verrijkt
Ook dit jaar hebben de wetenschappelijke verenigingen alles op alles gezet voor een programma dat prikkelt en verdiept, met nationale en internationale sprekers van naam. De academische sessie wordt bovendien gekleurd door enkele internationale key opinion leaders. En er is een bijzonder moment weggelegd voor **professor Marie-Josée Tassignon**, die we huldigen voor een schitterende en inspirerende loopbaan.

Leren door te doen
In de interactieve **klinische cursussen (ICC)** en de **wetlabs** schuift u zelf aan, probeert u uit en gaat u naar huis met vaardigheden die u morgen al in uw praktijk kunt inzetten.

Samen vooruitkijken
Onze **industriepartners**, zonder wier steun dit congres niet mogelijk zou zijn, presenteren hun nieuwste ontwikkelingen op de expositie. Het is de uitgelezen plek om vragen te stellen en plannen te smeden voor het jaar dat komt.

We sluiten traditiegetrouw af met een uitgebreide sessie **ethiek en economie**, een helder en bruikbaar kompas voor de toekomst van uw praktijk. Een mooi moment om de balans op te maken nu het jaar ten einde loopt, en een afsluiter die zelden een lege zaal kent.

Een avond om te onthouden
Op **donderdagavond** komen we samen voor het **congresdiner met aansluitende party**, een avond waaraan deelnemers telkens met een glimlach terugdenken. Het ideale moment om alvast het glas te heffen op het voorbije jaar. Wat er op de dansvloer gebeurt, laten we in collegiaal stilzwijgen gehuld.

Een rustpunt, een hoopvol begin
We leven in uitdagende tijden, financieel, economisch, geopolitiek en klimatologisch. Net daarom geloven we in de kracht van samenkomen. Laat OB 2026 een rustpunt zijn waar we ideeën delen, elkaar sterken en nieuwe moed vinden.

Want als het jaar ten einde loopt, kijken we vanzelf vooruit. Wij koesteren de hoop op een betere toekomst, vol vrede en voorspoed, voor u, uw dierbaren, uw patiënten en de wereld om ons heen. Samen zien we de toekomst nu eenmaal scherper, en in zulk goed gezelschap lijkt ze nu al een stuk helderder.

Wij kijken ernaar uit u te ontmoeten en wensen u een inspirerend congres, gevolgd door een warme en zalige eindejaarsperiode.

Met collegiale groeten,

Werner Dirven
Voorzitter OB 2026, namens het organiserend comité van OB

Préface



Chers collègues,

Il est des jours où une discipline se montre sous son plus beau jour : lorsque plusieurs générations d'ophtalmologues se réunissent, partagent leur savoir et se rappellent pourquoi elles ont un jour choisi ce magnifique métier. Du **mercredi 25 au vendredi 27 novembre 2026**, ce seront précisément ces jours-là. C'est avec un grand enthousiasme que nous vous invitons à la **33e édition d'Ophtalmologica Belgica, OB 2026**, à nouveau dans le cadre bien connu du **Square**, au cœur de Bruxelles, tandis que la ville s'habille peu à peu de lumières de fête.

Ce qu'aucun écran ne peut offrir
L'information est partout disponible, et nos réunions se tiennent désormais depuis le canapé. Mais l'inspiration naît rarement seule devant un écran. Elle grandit dans les couloirs entre deux sessions, dans un échange d'idées inattendu, dans les retrouvailles avec un vieil ami. Et soyons honnêtes : aucune pause-café virtuelle ne vaut la vraie.

Un programme qui stimule et enrichit
Cette année encore, les sociétés scientifiques ont tout mis en œuvre pour proposer un programme qui interpelle et approfondit, avec des orateurs nationaux et internationaux de renom. La session académique sera en outre enrichie par la présence de plusieurs key opinion leaders internationaux. Un moment tout particulier sera consacré à la **professeure Marie-Josée Tassignon**, à qui nous rendrons hommage pour une carrière brillante et inspirante.

Apprendre en faisant
Dans les **cours cliniques interactifs (ICC) et les wetlabs**, vous prenez place, vous essayez, et vous repartez avec des compétences que vous pourrez mettre en pratique dès demain dans votre cabinet.

Regarder l'avenir ensemble
Nos **partenaires industriels**, sans le soutien desquels ce congrès ne serait pas possible, présenteront leurs dernières avancées lors de l'exposition. C'est l'endroit idéal pour poser vos questions et forger vos projets pour l'année qui vient.

Comme le veut la tradition, nous clôturerons par une session approfondie consacrée à l'**éthique et à l'économie**, une boussole claire et utile pour l'avenir de votre pratique. Un beau moment pour faire le point alors que l'année touche à sa fin, et une conclusion qui voit rarement une salle vide.

Une soirée à retenir
Le **jeudi soir**, nous nous retrouverons autour du **dîner de congrès, suivi de la soirée dansante**, une soirée dont les participants gardent chaque fois un souvenir souriant. L'occasion idéale de lever dès à présent son verre à l'année écoulée. Ce qui se passe sur la piste de danse, nous le couvrons d'un silence confraternel.

Une halte, un nouveau départ plein d'espoir
Nous vivons des temps exigeants, sur les plans financier, économique, géopolitique et climatique. C'est précisément pourquoi nous croyons en la force du rassemblement. Que l'OB 2026 soit une halte où l'on partage des idées, où l'on se renforce mutuellement et où l'on retrouve du courage.

Car lorsque l'année s'achève, le regard se tourne naturellement vers l'avenir. Nous formons le vœu d'un avenir meilleur, empreint de paix et de prospérité, pour vous, vos proches, vos patients et le monde qui nous entoure. Ensemble, nous voyons décidément l'avenir avec plus de netteté, et en si bonne compagnie, il paraît déjà bien plus lumineux.

Nous nous réjouissons de vous rencontrer et vous souhaitons un congrès riche en inspiration, suivi de très belles fêtes de fin d'année.

Avec nos salutations confraternelles,

Werner Dirven
Président de l'OB 2026, au nom du comité organisateur de l'OB

THANK YOU TO OUR

SPONSORS






















































PRECISION


Luce Care


MEDICAL
DevEyes


MediPut


Moria


mpt


NewVision


NORDIC
PHARMA


Oftahils


OPHTALMO
SURGICAL


OPHTAZON
Europe


optos


plusoptix
made in Germany


Pro-Vision


ZEISS


REVOGAN


ROCKMED vision



RODENSTOCK
Because every eye is different


SAMSUNG
BIOEPIS


SANDOZ


Santen


SIMOVISION
A HILCO VISION COMPANY


SJJ Solutions


STERIBEL
www.steribel.com


TECHNOP
YOUR PARTNER
IN VISION

continues >>

THANK YOU TO OUR

SPONSORS

OB Programme

OB Progamme overview by day

WEDNESDAY | 25 NOVEMBER 2026 |

	COPPER	SILVER	HALL 100	HALL 300	COPPER FOYER	SPEAKERS CORNER
09:00-10:30	OBAO		ICC-1	ICC-2	WETLAB-1 Glaucoma (dryblab)	AOB e-posters ↓
10:30-11:00	BREAK 10:30 - 11:00					Hasa Optix - Ind. Session
11:00-12:30	ACADEMIC SESSION (Plenary) in room Copper AOB Lecture, Keynote speakers					
12:30-14:00	LUNCH BREAK 12:30-14:00					AOB Rapid-Fire CooperVision - Ind. Session
14:00-15:30	OBAO	BSCRS	ICC-3	AOB FREE PAPERS 1	WETLAB-2 Phaco Beginners NL	
15:30-16:00	BREAK 15:30 - 16:00					Luce Care - Ind. Session
16:00-17:30	OBAO	BSCRS	ICC-4	AOB FREE PAPERS 2	WETLAB-3 Cornea and Iris Sutures	
17:30-18:30		SATELLITE SYMPOSIUM AMGEN Access MDs only	AOB Board & General Assembly			

dd09-11-2026 see program online for the most update version

THURSDAY


| 26 NOVEMBER 2026 |

	COPPER	SILVER	HALL 100	HALL 300	COPPER FOYER	SPEAKERS CORNER
07:45-08:45			SATELLITE SYMPOSIUM SANTEN Access MDs only			AOB e-posters ↓
09:00-10:30	BRS	BGS	BSA	ICC-5	WETLAB-4 Phaco Beginners NL	
10:30-11:00	BREAK 10:30 - 11:00					Luce Care - Ind. Session
11:00-12:30	BRS	BGS	BSA	ICC-6	WETLAB-5 Phaco Beginners NL	
12:30-14:00	LUNCH BREAK 12:30-14:00					SJJ Solutions - Ind. Session CooperVision - Ind. Session
14:00-15:30	BRS	BSOPRS	PEDLOWNOC	ICC-7	WETLAB-6 Glaucome	
15:30-16:00	BREAK 15:30 - 16:00					Laméris - Ind. Session
16:00-17:30	BRS	BSOPRS	PEDLOWNOC	ICC-8	WETLAB-7 Phaco Beginners FR	
CONGRESS DINNER PARTY						

dd09-11-2026 see program online for the most update version

OB Progamme overview by day

FRIDAY | 27 NOVEMBER 2026 |



dd09-11-2026 see program online for the most update version

Stellest®
2.0 Lenses

Essilor®

#1 lens brand

recommended by eye care professionals worldwide*



Twice the power,† higher efficacy‡1,2

Essilor® Stellest® 2.0 lenses provide twice the signal for slowing myopia progression,§ delivering significantly better results.‡1,2

*Based on an average recommendation with quantitative research conducted in 8 countries (Brazil, Canada, China, France, India, Italy, UK, and the US) among a representative sample of 1560 Eye Care Professionals: 1047 opticians, 513 optometrists between January and June 2022. These 8 countries represent: 63% of total world in lens volume. †Twice the power refers to two (or more) times the depth of volume of non-focused light (by design) compared to that of Essilor® Stellest® lenses, and is not associated with twice the lens or lenslet power. Additionally, this does not imply a corresponding doubling of efficacy in slowing myopia progression. ‡Based on 12-month results from a prospective, randomized, double-masked contralateral crossover clinical trial conducted in Singapore on 50 children, in which one eye was equipped with an Essilor® Stellest® lens and the other with Essilor® Stellest® 2.0 lens. §Twice the signal refers to two (or more) times the depth of volume of non-focused light (by design) compared to that of Essilor® Stellest® lenses and is not associated with twice the lens or lenslet power. Additionally, this does not imply a corresponding doubling of efficacy in slowing myopia progression. 1. Raveendran RN, Ong WS, Lim SY, Lim EW, Chua HR, Drobe B. Effect of increased power and asphericity of lenslets on myopia control efficacy: 6-month interim results of a contralateral crossover clinical trial. Invest Ophthalmol Vis Sci. 2025;66:5192 2. Raveendran RN, Ong WS, Wong YL, Zhan SJ, Lee CF, Lim SY, Drobe B. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9. doi:10.1167/tvst.14.11.9.

© Essilor International – June 2025. Essilor®, Evolving Vision™ and Stellest® are trademarks of Essilor International

essilor

evolving vision

EssilorLuxottica

Dry AMD: Promising Results After 12 Months

The multicentre, randomised, double-masked DRUSEN study demonstrates a reduction in drusen volume and an improvement in visual function.



eye-light®

Photobiomodulation
Non-invasive light therapy for patients with dry AMD.

espansione group

Discover the First Results of the Ongoing Study
Scan the QR code to access the full publication.
(Product Eye-Light / Additional Information, Downloads tab)

Want to learn more?
Visit us at the OB Congress (25–27 November) and discover he latest clinical insights into photobiomodulation.

Essilor Instruments • Keizer Karellaan 586, 1082 Sint-Agatha-Berchem • www.instruments.essilor.be

ESSILOR INSTRUMENTS

WEDNESDAY | 09:00 - 10:30 | **COPPER**

Emergencies in ophthalmology: what's new and what's important?

Moderators: Amira FARAJ, Maximiliaan ZEYEN

09:00 **Management of thermal and chemical ocular burns**
ROELS D

09:20 **Nystagmus in children**
VAN AERSCHOT J

09:40 **Therapy of macular haemorrhage**
VECKENEER M

10:00 **Postoperative endophthalmitis, when to inject and when to operate?**
VAN CALSTER J

10:30 *End of Session*

WEDNESDAY | 11:00 - 12:30 | **COPPER**

AOB Academic session

Moderator: Werner DIRVEN

11:00 *Welcome by Dr Werner Dirven - President OB 2026*

11:02 *Introduction of Keynote Lecture 1 by Dr Werner Dirven*

11:04 **From Artificial General Intelligence to Artificial Medical Intelligence**
KEANE P

11:24 *Introduction of Keynote Lecture 2 by Dr Nathalie Collignon*

11:26 **The latest advances in glaucoma surgery**
MERCIECA K

11:46 *Introduction of AOB Lecture by Dr Luc Van Os*

11:48 **AOB LECTURE:**
Accomplishments and future objectives driven by collective synergy
TASSIGNON MJ

12:08 *Introduction of Keynote Lecture 3 by Dr Maëlle Coutel*

12:10 **Diamonds in the Rough**
NI DHUBHGHAILL S

12:30 *End of Session*

COPPER

AOB Lecture



Laureate AOB Lecture 2026

Prof. Dr. Marie-José Tassignon
Brussels, Belgium

She received her training in Medicine and Ophthalmology at the VUBrussels.

Her most significant contribution to the progress in ophthalmology was the development of the Bag-in-the-lens and description of developmental anomalies of the anterior interface of the eye.

She initiated inter-university collaboration in Belgium by (co)-creating FRO, AOB, BSCRS, COB, Be-Vision.

Translational research and clinical excellence resulted in a substantial number of publications, books and patents.

Internationally, she served ESCRS - EBO and AOI as president.

She received 19 medals and awards out of which: Binkhorst medal, Norman Galloway award, Peter Eustace award, Montgomery medal, Tadeusz Krwawicz Gold Medal, Teddy Epstein Medal, Bjerrum Medal, Kanski medal, Lifetime Achievement medal EPOS, EyeCon 21st Century.

She received academic awards: Member of the Royal Academy of Medicine, Ukranian Academy, Honorary Professor of Chinese State Key, Honoris Causa University of Iasi – Romania.

WEDNESDAY | 14:00 - 15:30 | **COPPER**

Emergencies in ophthalmology: what's new and what's important?

Moderators: Amira FARAJ, Juliette LEVIE

14:00 **Malignant glaucoma: key signs and management**
DUGAUQUIER A

14:20 **Postoperative hypotony management**
LEMMENS S

14:40 **Acute retinal necrosis: How to recognise and react**
SCHAUWVLIEGHE P

15:00 **Retinal artery occlusions: early actions and diagnosis**
JACOB J

15:30 *End of Session*

WEDNESDAY | 16:00 - 17:30 | **COPPER**

Emergencies in ophthalmology: what's new and what's important?

Moderators: Amira FARAJ, Ameli SHERVINE

16:00 **Differentiating optic neuritis from NMO and MOG**
CHAPELLE A

16:20 **Sudden visual loss after 50: is it really NAION?**
ALSADDI M

16:40 **Orbital haemorrhage, to cut or not to cut?**
GOEMAERE J

17:00 **Orbital fracture, is surgery necessary and when?**
DE GROOT V

17:30 *End of Session*

WEDNESDAY | 14:00 - 15:30 | **SILVER**

Complications in Cataract Surgery

Moderators: Guy SALLET, Françoise VAN CAUWENBERGE

14:00 *Session 1: Complications in Cataract Surgery*

14:00 *INTRA-OPERATIVE*

14:00 **How to manage 1st steps of surgery: Incisions and Capsulorhexis**
VAN OS L

14:10 **Posterior capsule rupture**
PION B

14:20 **Floppy Iris Syndrome and Narrow pupil**
GOES F

14:30 **Zonular weakness**
DERVEAUX T

14:40 **Avoiding Nightmares in cataract surgery: don't make it worse**
VAN CAUWENBERGE F

14:50 *POST-OPERATIVE*

14:50 **The painful red eye post op**
NI DHUBHGHAILL S

15:00 **Irvine-Gass syndrome**
FASOLINO G

15:10 **Refractive surprise**
AL-SABAI N

15:20 *Q&A*

15:30 *End of Session*

WEDNESDAY | 16:00 - 17:30 | **SILVER**

Complications in Refractive Surgery

Moderators: Dany SALIK, Thierry DERVEAUX

16:00 *SESSION 2: Complications in Refractive Surgery*

16:00 **Intra-operative complications in LASIK**
SALLET G

16:15 **Post-operative complications in LASIK**
GOLENVAUX B

16:30 **Complications in SMILE surgery**
DE WILDE F

16:40 **Post-operative complications in surface ablation**
CHAPELLE JF

16:50 **Complications in phakic lens surgery**
SALIK D

17:00 **Complications in Refractive Lens Exchange**
CRAHAY FX

17:10 **Avoidance of post-operative dry eye**
KOPPEN C

17:20 *Q&A*

17:30 *End of Session*

THURSDAY | 09:00 - 10:30 | COPPER

Retina Surgery for the Non-Surgeon
A Practical Guide to Referral and Co-management

Moderators: Peter STALMANS, Leigh SPIELBERG

09:00 **Endophthalmitis: What to Do When Every Hour Counts**
DE CLERCK I

09:12 **After Vitrectomy: Reassure, Review… or Refer Back?**
STALMANS P

09:24 **Submacular Hemorrhage: Observe, Inject… or Operate**
LEPIECE G

09:36 **Bubble Trouble: When Tamponades Go Wrong**
BALI E

09:48 **Retinal Tears & Detachments: Laser, Refer… or Rush to Surgery?**
ACCOU G

10:00 **Macular Pucker Surgery: Too Early, Too Late… or Just Right?**
VECKENEER M

10:12 *Interactive Panel Discussion & Clinical Cases - by Faculty*

10:30 *End of Session*

THURSDAY | 11:00 - 12:30 | COPPER

One Patient, Many Specialists When the Retina Tells a Bigger Story

Moderators: Werner DIRVEN, Julie DE ZAEYTIJD

11:00 **The Incidental Retina: When the Eye Reveals the Unexpected**
RAMTOHUL P

11:20 **Vascular Tumors, Masquerades and Diagnostic Traps**
QUHILL H

GIANT CELL ARTERITIS: CLEAR-CUT DISEASE OR GREY ZONE MEDICINE?

11:40 **Part 1 - Diagnostic Dilemmas in Real-World Practice**
CHAPELLE A

12:00 **PART 2 - Treatment Controversies & Novelties**
DE CRAEMER AS

12:20 **PART 3 - Multidisciplinary**
Panel Discussion - Retina, Neuro-ophthalmology and Rheumatology

12:30 *End of Session*

THURSDAY | 14:00 - 15:30 | **COPPER**

Systemic Disorders and Uveitis: Focus on Granulomatous Disease

Moderators: Alexandra KOZYREFF, François WILLERMAIN

14:00 **Granulomatous Disease: Definitions, Mechanisms and Differential Diagnosis**
SCHAUWVLIEGHE P

14:10 **Ocular Sarcoidosis and Tuberculosis : Two Faces of the Same Coin ?**
KOZYREFF A

14:25 **KEYNOTE LECTURE**
Ocular Tuberculosis: From Pathogenesis to Treatment
VAN HAGEN M

14:50 **Why Histopathology Still Matters in Granulomatous Disease**
VAN CALSTER J

15:00 **Challenging Cases: When the Diagnosis Refuses to Fit**
TEN BERGE J

15:20 *Interactive Panel Discussion*

15:30 *End of Session*

THURSDAY | 16:00 - 17:30 | **COPPER**

Interactive Mystery Cases and Diagnostic Challenges

Moderator: Werner DIRVEN

16:00 *Case Presentations*

17:30 *End of Session*

THURSDAY | 09:00 - 10:30 | **SILVER**

Glaucoma Fight Club: The Decisions That Divide Us

Moderators: Ingeborg STALMANS, Stefan KIEKENS

SESSION 1: First Line Fireworks

09:00 **Welcome and Introduction: How to Vote, How to Fight Fair**
STALMANS I

09:05 **First Shot: Drops or SLT?**
VAN EIJGEN J, DUGAUQUIER A

09:20 **Neuroprotection: Holy Grail or Hot Air?**
VAN DE VEIRE S, HONDEGHEM K

09:35 **More Bottles or the Knife? Maximal Medical Therapy versus Early Surgery**
VANDEWALLE E, COLLIGNON N

09:50 *SPEAKERS PANEL: Crossfire Discussion:*
When Do We Stop Escalating and Start Acting?

10:00 **Invited International Lecture:**
The Eagle Eye Perspective on non-surgical options
MERCIECA K

10:25 *Take-Home Messages by the Moderators*

10:30 *End of Session*

THURSDAY | 11:00 - 12:30 | **SILVER**

Glaucoma Fight Club: The Decisions That Divide Us

Moderators: Ingeborg STALMANS, Stefan KIEKENS

SESSION 2: Surgery Showdowns

11:00 **Phaco Solo or Phaco-MIGS:**
Clever Add-On or Costly Decoration?
EHONGO A, POURJAVAN S

11:15 **Secondary Glaucoma:**
Trab or Tube? Choose Your Weapon
DE GROOT V, LEMMENS S

11:30 **The Right Cut for the Right Eye:**
Individualised Glaucoma Surgery in Real Life
MERCIECA K

11:55 **Rapid-Fire Cases: What Would You Do?**
BY KARL MERCIECA AND ALL SPEAKERS

12:25 *Closing Remarks by Ingeborg Stalmans*

12:30 *End of Session*

THURSDAY | 14:00 - 15:30 | **SILVER**

Better not operate

Moderators: Yasmin ALI SAID, Arnaud POTVIN

14:00 **Treat the cause, not the consequence**
MOREAU A

14:15 **The waiting game**
HELSEN S, CAEN S

14:30 **Avoiding SIMON, embracing SYLVIA: recognising and managing red flag patients**
POTVIN A, SAID YA

14:45 **Lower eyelids can be tricky, better think twice**
DE GROOT V

15:00 **When imaging is missing**
DE LEPELEIRE K

15:15 *Discussion*

15:30 *End of session*

THURSDAY | 16:00 - 17:30 | **SILVER**

Better not operate

Moderators: Yasmin ALI SAID, Arnaud POTVIN

16:00 **Alternative treatments in peri-ocular malignancies: What to do without the knife?**
GOEMAERE J

16:20 **Will non-surgical treatment replace surgery for thyroid eye disease?**
POTVIN A

16:40 *Quiz*

17:30 *End of session*

THURSDAY | 09:00 - 10:30 | HALL 100

Surprising recent insights to avoid the scissors

Moderators: Lavinia POSTOLACHE, Coralie HEMPTINNE

09:00 **Welcome**
by BSA President Dr Sandrine De Temmerman

09:10 **In memoriam: Daisy Godts**

09:20 **BSA grant**
JARDINET M

09:30 **BSA Grant**
VERMEERSCH E

09:40 **Keynote Speaker:**
Use of Botox in strabismus management (UK)
HANCOX J

10:20 *Discussion*

10:30 *Break*

THURSDAY | 11:00 - 12:30 | **HALL 100**

Surprising recent insights to avoid the scissors

Moderators: Lavinia POSTOLACHE, Coralie HEMPTINNE

11:00 **Eye screening in Belgium**
VAN AERSCHOT J

11:20 **Final results of the Early Glasses Study**
STELTMAN J

12:00 *Panel discussion with all speakers*

12:30 *End of Session*

THURSDAY | 14:00 - 15:30 | **HALL 100**

Guidelines in Ophthalmology

Moderators: Ingele CASTEELS, Antonella BOSCHI

14:00 **Retinopathy of prematurity: screening and treatment**
CASTEELS I

14:25 **Vernal Keratoconjunctivitis**
DUCHESNE B

14:50 **Management of Stickler syndrome Introduction: classification and clinical findings**
VERLEYEN E

15:00 **Management of Stickler syndrome**
Round table discussion
PANEL: ACCOU G, STALMANS P, RAKIC JM, NERINCKX F

15:30 *BREAK*

THURSDAY | 16:00 - 17:30 | **HALL 100**

Guidelines in Ophthalmology

Moderators: Ingele CASTEELS, Antonella BOSCHI

16:00 **Intracranial hypertension**
TOUITOU V

16:30 **Optic Neuritis**
CHAPELLE A, COUTEL M

17:00 **Rapid fire presentations**
BALIKOVA I

17:30 *Closing Remarks and Awards*

FRIDAY | 09:00 - 10:30 | **GOLD**

From Neverland to Adulthood

Moderator: Perrine GILLARD

09:00 *Welcome*

EYELID PATHOLOGY: BLINKING BETWEEN CHILDHOOD AND ADULTHOOD

09:10 **Pediatric Eyelid Pathology**
DE GROOT V

09:20 **Young Adult Eyelid Pathology**
BALDESCHI L

STRABISMUS: LOST ALIGNMENT IN NEVERLAND

09:30 **Pediatric Strabismus**
HEMPTINNE C

09:40 **Adult Strabismus**
CASSIMAN C

UVEITIS: THE FIRE BEHIND THE EYE

09:50 **Pediatric Uveitis**
DRAGANOVA D

10:00 **Young Adult Uveitis**
KREPS E

CATARACT: A CLOUD OVER NEVERLAND

10:10 **Pediatric Cataract Management**
VAN OS L

10:20 **Young Adult Cataract Management**
CRAHAY F

10:30 *Break*

FRIDAY | 11:00 - 12:30 | **GOLD**

From Neverland to Adulthood

Moderator: Dany SALIK

GLAUCOMA: CAPTAIN HOOK'S BLIND SPOT

11:00 **Glaucoma Across the Lifespan: Pediatric**
LEMMENS S

11:10 **Glaucoma Across the Lifespan: Young Adults**
EHONGO A

MYOPIA: NEVER-ENDING MYOPIA?

11:20 **From the Growing Eye to the Adult Myope: Pediatric**
RAMAEKERS A

11:30 **From the Growing Eye to the Adult Myope: Adult**
VAN BOL L

LOW VISION AND REHABILITATION: FINDING THE WAY WITHOUT THE MAP

11:40 **Low Vision Support Across Ages**
Team Low Vision UZA and Team Horus center ULB Brugmann

INTERACTIVE QUIZ / RED FLAGS: DON'T MISS THE CROCODILE!

12:00 **Interactive Red Flags Quiz**

12:30 *End of Session*

ETHICS

BBO-UPBMO

- Belgische Beroeps Vereniging van Oogheelkundigen
- Union Professionnelle belge des Médecins Spécialistes en Ophtalmologie et Chirurgie Oculaire

FRIDAY | 14:00 - 15:30 | **GOLD**

Ethical and Economic Developments in Ophthalmology

Moderators: Koen WILLEKENS, Stefaan VAN NUFFEL

14:00 **Introduction**
WILLEKENS K

14:05 **New legislation for the orthoptist:**
clinical and organizational impact of screening, diagnosis and treatment
VAN NUFFEL S

14:30 **Intermezzo: myopia control in Belgium**
DELBEKE P

14:35 **Intravitreal Injection Therapy:**
Clinical Innovation, Reimbursement and Sustainability
GOETHALS S

14:50 **Nomenclature, Reimbursement and Transparency codes:**
Ethical and Economic Perspectives
WILLEKENS K

15:25 *Questions*

15:30 *End of Session*

FRIDAY | 16:00 - 17:30 | **GOLD**

Professional Responsibility and The Future of Ophthalmology

Moderators: Marnix CLAEYS, Reza LADHA

16:00 Introduction
CLAEYS M

16:05 **The Changing Organization of Care in Belgium: Hospitals, Private Practice and Integrated Care**
MST STEVENS C

16:30 **Digital Professionalism: Social Media, AI, GDPR and Patient Confidentiality**
MST SMEUNINX E

16:50 **The Independent Ophthalmologist: Economic, Legal and Organizational Considerations**
MST MICHIELSEN L

17:20 *Questions*

17:30 *End of Session*

Attention — Scanning rules for ethics accreditation

We will once again be closely monitoring attendance during the ethics session. During each ethics session, a QR code will appear on the screen twice at random moments. You must scan both codes and enter your name and RIZIV number to register your attendance and secure your accreditation points, SO TWO SCANS PER SESSION = 4 SCANS IN TOTAL. We encourage you to keep your Friday free so you can attend the ethics session in person and earn your ethics points. Thank you for your cooperation and active participantion - together we ensure a smooth, valuable and enriching session!

Please read the full accreditation info here.

FRIDAY | 08:30 - 15:30 | **COPPER**

BSONT NL

08:30 *Verwelkoming & overzicht van het verloop van het congres*
Dr. Werner Dirven, OB 2026 President

08:45 **Resultaten van de bevraging tijdens het congres van 2025, instructies over het gebruik van de QR-code**
BLOMMAERT E

SESSIE 1: Rond het oog: van anatomie tot chirurgie
Moderatoren: Carine Segers en Eline Blommaert

09:00 **Wanneer de schildklier het oog op hol brengt: anatomie, pathologie en ziekte van Graves in de praktijk**
NINCLAUS V

09:20 **Als tranen niet meer wegvloeien: traanwegenpathologie en heelkunde in de praktijk**
ALI SAID Y

09:40 **Als het ooglid faalt: oogledenpathologie en heelkunde in de praktijk**
LAMBERT I

10:00 **Als het oog moet wijken: enucleatie, evisceratie en prothese-implantatie in de praktijk**
DE GROOT V

10:20 KOFFIEPAUZE

SESSIE 2: Wanneer ZIEN verandert?
Moderatoren: Eline Blommaert en Charlotte Pieters

11:00 **Als de telefoon het eerste hulpmiddel is: triage en eerste opvang bij acute oogklachten**
THERSSEN N

11:30 **Als scherp zien niet meer vanzelfsprekend is: low vision**
Werking van het centrum voor visuele revalidatie
DE REU C

11:45 **Van revalidatie naar werkvloer: low vision ondersteuning bij de arbeidsmarkt**
VERMEULEN K

12:00 **Nieuwe wegen zonder zicht: mentale veerkracht en ondersteuning bij visusverlies**
LETTANIE A

12:30 LUNCH

SESSIE 3: Verder dan het zichtbare — het netvlies als venster op ziekte
Moderatoren: Charlotte Pieters en Carine Segers

14:00 **Denk. Scan. Check. De kwaliteit van de OCT-scan in jouw handen**
DE ZAEYTIJD J

14:30 **Het netvlies onder druk — van suiker tot stolsel: ischemie, trombose en retinopathie**
TEZCAN F

15:00 **Het oog als spiegel van het lichaam: uveitis en systeempathologie**
SELS L

15:30 *EINDE*

FR

BSONT - Belgian Society of Ophthalmic Nurses and Technicians

FRIDAY | 09:00 - 15:30 | **COPPER**

BSONT FR

MODERATORS: Maria PIPIRIG, Daniela BRAD

09:00 *Accueil, inscriptions et café de bienvenue*

09:00 **Mot d'ouverture**
COUTEL M

09:10 **Préparer une chirurgie de la cataracte sans perdre le fil… ni le sourire**
ROSAPELLY B

09:30 **Implants premium et attentes des patients**
HUPIN N

09:50 **Après la chirurgie de la cataracte : surveillance et signaux d'alerte**
SELLAMI K

10:10 **Le parcours cataracte : de l'évaluation à la chirurgie**
VAN ACKER A

10:30 Pause-café

10:50 **Les bases du glaucome pour les infirmier(ère)s**
LOUSSE J

11:10 **Collyres, observance et éducation thérapeutique dans le glaucome**
SAAB C

11:30 **Rupture de fusion**
BROHEZ J

11:50 **Surface oculaire : le petit détail qui change tout**
BOURGUIGNON G

12:10 **Prévention des infections en ophtalmologie**
PIROUX C

12:30 Pause déjeuner

dd09-11-2026 see program online for the most update version

13:30 **Les injections intravitréennes : pratique infirmière et sécurité**
BUGHIN A

13:50 **Urgences ophtalmologiques : ce qu'il ne faut surtout pas manquer**
EL KORTOBI S

14:10 **Diabète et œil : un duo à surveiller de près**
GIELEN CE

14:30 **Glaucome interventionnelle**
POURJAVAN S

14:50 **Intelligence artificielle et innovation numérique en ophtalmologie**
HAULOT T

15:10 **Communication, empathie et accompagnement du patient malvoyant**
CASPERS S

15:30 *Clôture de la journée*

dd09-11-2026 see program online for the most update version

FRIDAY | 09:00 - 12:30 | **HALL 100**

All you need to know about visual rehabilitation

Moderators: Inge SEGERS, Remi GUERIN

09:00 **Welcome**
MAASSEN M

09:10 **Beyond the oculomotor nuclei:**
the vital role of the orthoptist in visual function Rehabilitation
BAUWENS A

09:40 **Orthoptics at the Crossroads of Otorhinolaryngology, Neurology and Ophthalmology**
MARLAIR C

10:10 **Orthoptics in Low Vision Rehabilitation**
LAMOT L

10:40 *Break*

11:15 **Orthoptics in CVI**
BENI K

11:45 **Orthoptics in Neuro-Visual Rehabilitation**
BOORE L

12:15 *Cases*

12:30 *End of Session*

FRIDAY | 13:00 - 13:30 | HALL 100

Award Ceremony

FRO Laureat 2026 (15min)
Presented by Bart Leroy - Marie-Jose Tassignon

OB 2026 Best Poster / Best Free Paper / Best Rapid Fire
Presented by Jozef Depla

COB Cataract Surgery Training - Presentation of certificates
for participants who successfully completed the course in the 2025-2026 academic year
Presented by Carina Koppen

MyDay® contactlenzen

Eén merk. Eén familie. Een leven lang lenzen dragen.

Silicone hydrogel: van myopiecontrole tot presbyopie

Ondersteund door Aquaform® Technology

Uitzonderlijk comfort de hele dag door[1] en hoog zuurstofdoorlatend[1], voor elke levensfase.







Benieuwd wat MyDay® voor uw praktijk kan betekenen? Bezoek ons op stand 22. ook tijdens speakerscorner op woensdag en donderdag om 13.30u

CooperVision®

SA20691

AOB Free Papers

WEDNESDAY | 14:00 - 15:30 | HALL 300

AOB Free Papers 1

14:00 **Cataract Surgery in Patients with Inherited Retinal Dystrophies: Pre-, Intra- and Postoperative Management**
ALLUYN L, HOEBEKE L, ROELS D

14:10 **Therapeutic Drug Monitoring of Adalimumab in Paediatric non-infectious Uveitis: A Retrospective Analysis**
PARK C, BONROY C, DEHOORNE JL, KREPS EO

14:20 **Keeping the visual axis clear: Double optic capture in paediatric cataract surgery**
VERLEYEN E, CASTEELS I, CASSIMAN C, VAN AERSCHOT J, SAELENS I

14:30 **Early management of vitreous hemorrhage : clinical experience of the University Hospital of Liege**
RAKIC N, VAN CAUWENBERGE F, GEORGES A, RAKIC JM

14:40 **Oculomotor Phenotyping for Neurological and Neuromuscular Dysfunction**
ROSELETH L, CASSIMAN C

14:50 **Radiation Retinopathy in patients with Ruthenium brachytherapy for uveal melanoma**
MISSOTTEN G, WASSOUF M., CHRISTIAENS M., DE CLERCK I, VAN CALSTER J

15:00 **Minimally Invasive Bleb Surgery (MIBS) in Patients at High Risk of Trabeculectomy Failure: A Scoping Review**
DEMEESTERE D, JACOBS T, MARTIN KR, KERR NM, VAN EIJGEN J, STALMANS I

15:10 **Determinants of anatomical and functional outcomes after surgery for rhegmatogenous retinal detachment: a 10-year tertiary-center cohort study**
BARAKAT S, LIPSKI D, MOTULSKY E

15:20 *Discussion*

15:30 *End of Session*

WEDNESDAY | 16:00 - 17:30 | HALL 300

AOB Free Papers 2

16:00 **Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients with Severe Dry Eye Disease: a prospective, blinded, randomized, crossover study**
ROELS D, LEROY BP, CLAERHOUT I, KERRE T

16:10 **Case report: DALK followed by DMEK**
MYLEMANS E, MOOREN P

16:20 **The combination of a narrowed and extended partial depth-of-field intraocular lens (COMEDI) in bilateral cataract surgery**
VAN SCHOOR R, TERMOTE K

16:30 **Overcoming aciclovir resistance in herpetic keratitis**
RENS J

16:40 **Early clinical outcomes after implantation of corneal allograft ring segments (CAIRS) for the treatment of keratoconus**
OLLIVIER R, NUIJTS RMMA

16:50 **The importance of fluo-angiographic evaluation of retinopathy of prematurity**
PULYAVINA A, VAN SEVEREN V, VAN ZEEBURG EJT

17:00 **Phototherapeutic Keratectomy as an Alternative Treatment Modality for Persistent Epithelial Defect after Alkali Chemical Injury: A Case Report**
ATALAY G, KOPPEN C

17:10 **Retinal vasculature across primary open-angle glaucoma severity groups: a cross-sectional study**
VAN EIJGEN J, VERCRUYSSE J, GHINIS A, BEECKMANS L, MOLENBERGHS G, VENS C, STALMANS I

17:20 *Discussion*

17:30 *End of Session*

WEDNESDAY | 12:45 - 13:30 | SPEAKERS CORNER

AOB Free Papers: Rapid Fire Session

Moderator: Jozef DEPLA, Sorcha NI DHUBHGHAILL

106 12:45 **The Hidden Power of Sleep on Eye comfort**
VOORSPOELS L, DELBEKE H, SAELENS I, LAUREYS S, JANSEN L, MEEREMANS L

135 12:45 **Intravitreal aflibercept and laser therapy in the treatment of retinopathy of prematurity; retrospective cohort study over 2,5 years**
DE VETTER S, VERDONCK T, VAN ZEEBURG EJT

136 12:50 **Decoding growth factor profiles of platelet-derived eye drops for ocular surface disease: a systematic review of preparation, preservation and comparison with serum eye drops**
COOLS L, ORBIE S, VAN REMOORTEL H, SIX KR, FEYS HB, SAELENS IEY, DELBEKE H

137 12:55 **Driving Forces and Perceived Barriers for the Adoption of Novel Endothelial Cell Therapies: An International Survey of Corneal Surgeons**
LUAN Y, Ní DHUBHGHAILL S, ROSE-NUSSBAUMER J, DE KORT C, ROMANO V, OELLERICH S

138 13:00 **Visual, Refractive and Tomographic Outcomes After Mitomycin-Free Manual Superficial Keratectomy for Salzmann Nodular Degeneration and Peripheral Hypertrophic Subepithelial Corneal Degeneration: A Retrospective Cohort Study**
HOUBEN I, MOURISSE S, DERVEAUX T, VAN GREMBERGHE I, KREPS E, ROELS D

139 13:05 **From Legs to the Eye: A Potential Corneal Manifestation of X-linked Ichthyosis**
ZEYEN A, SAELENS I, DELBEKE H

140 13:10 **Evaluation of the iStent Inject® W trabecular micro-bypass stent combined with cataract surgery in cases of controlled chronic open-angle glaucoma – Results at 1 year**
LESOINNE P, DUPONT G, GUILLAUME S, COLLIGNON

141 13:15 **Predictive Value of OCT Biomarkers in Patients with Persistent Diabetic Macular Edema Undergoing Cataract Surgery Combined with a Dexamethasone Intravitreal Implant**
LAZAAR M, PROF FASOLINO

142 13:20 **Exploring topical losartan for corneal scarring: which scars show regression?**
AMELI S, KROLO I, OELLERICH S, NÍ DHUBHGHAILL S

ORTOPAD®

ORTOPAD® Mix PREMIUM stands for a great wearing comfort and a large choice of colourful motifs of eye patches.

Meet us at the OB 2026 Booth 21





Order **ORTOPAD® Mix PREMIUM** now, per box of 100 patches.
The 100 patches are **chosen by the child,** in multiples of 10, from 30 motifs.
Available in three sizes: Junior, Medium, Regular



OPS eyewear

Available at any optician, distributed by OPS Eyewear:
www.eyewear.be
Contact via e-mail at **sales@eyewear.be**
or by phone at **+32 (0)3 293 51 16**

A93196/A5/10-2026

E-POSTERS

All e-Posters on show during the entire congress at the speakers corner.

SPEAKERS CORNER

101 **Diagnosis and Management of Atypical Lipomatous Tumor of the Orbit: A Case Report**
RUYSSCHAERT E, ROELS D, NINCLAUS V

102 **Contact lens-related Parengyodontium album fungal keratitis: a Case Report**
VAN BUYNDER C, ROELS D, BOELENS J

103 **Ocular contrapulsion in a patient with lateral medullary syndrome**
SEDER A, NGADI M, BUELENS T

104 **Visual Snow Syndrome and Hallucinogen Persisting Perception Disorder: Clinical Characteristics, Diagnostic Challenges and Therapeutic Approaches in a Cohort**
NEMR A, BOYER C, COUTEL M

105 **Effects On Intraocular Pressure Of Combined Micropulse Transscleral Laser Therapy With Phacoemulsification : One Year Follow up And Comparison Between Two Different Protocols**
DEQUINZE M

106 **Refractive Predictability Following Cataract Surgery in Eyes with Clinically Significant Corneal Pathology**
BHARGAV J

107 **Next-Generation Sequencing for Excised Conjunctival Naevi: Does More Data Equal Better Care?**
VANDERMEULEN M, DIMITRI R

108 **Guideline Adherence of General-Purpose and Retrieval-Augmented AI Chatbots in Glaucoma Care: A Benchmark Study Against the EGS Guidelines**
JACOBS T, PONETTE L, COLSON A, VAN EIJGEN J, STALMANS I

109 **Atypical Bacterial Keratitis treated with Atypical Antibiotics – Clinical Application and Outcome of topical Amikacin, Azithromycin and Linezolid drops**
NAESSENS N, KREPS E, HOUBEN I, HUYS L, ROELS D

110 **For ROP treatment, a 4 mm, 32G TSK needle, might be a more guarded option for administration of aflibercept with a picleo pediatric dosing device**
VAN ZEEBURG E, VAN HAL B, AELBRECHT G

AOB e-Posters

All e-Posters on show during the entire congress

SPEAKERS CORNER

111 **Evaluation of one-year surgical outcomes of combined pars plana vitrectomy and Paul glaucoma implantation in the vitreous**
COLLEE C, VAN CAUWENBERGE F, KOUAM C, RAKIC J-M, COLLIGNON N

112 **Odyssey study**
NOLLET E, BLANCKAERT J, WALGRAVE V, MULLIEZ E, GHEKIERE S, NIJS J

113 **A Rare Ocular Manifestation of Undiagnosed Prostatic Adenocarcinoma: A Case Report**
COUTEL M, DUBOIS AD,

114 **Improvement of Chorioretinal Folds after Teprotumumab in Severe Graves' Orbitopathy**
JOOS B, VAN HAECKE H, VAN DEN BRUEL A, VANDELANOTTE S

115 **Paradoxical Worsening of Hypopyon Despite Clinical Improvement in Fusarium Keratitis: A Case Report**
ATALAY G, KOPPEN C

116 **Steroid-Responsive Orbital Apex Neuropathy With Multifocal Meningeal Thickening: A Diagnostic and Therapeutic Dilemma**
EL KORTOBI S, GUESSOUS Y, GUAGNINI AP

117 **When the eye reveals systemic disease: peripheral ulcerative keratitis as the presenting sign of anti-MDA5-positive dermatomyositis**
GUESSOUS Y, ZAFAD R, DIOURI S

118 **Photobiomodulation in Reticular Pseudodrusen-Associated Dry Age-Related Macular Degeneration: Effects on Geographic Atrophy, Photoreceptor Degeneration and Retinal Sensitivity**
MIRZA M, ROSE JR

119 **Amniotic membrane plugging for posterior retracted retinal breaks and breaks asssociated with chorioretinal atrophy: A silicone oil–sparing technique**
NAJIB A

120 **Reduced conjunctival blood flow: a new clinical sign for the diagnosis of ocular ischemic syndrome**
NAJIB A, RAKIC NATACHA NR

121 **Alpha-gal Allergy and Cataract Surgery**
VAN STYVENDAEL I, DUGAUQUIER A

SPEAKERS CORNER

122 **Reversible limbal ischemia and complete re-epithelialization after bilateral ammonia burn**
KEYTSMAN E, SALMAN S A, KROLO I, NI DHUBHGHAILL S

123 **Ocular adverse events in atopic dermatitis patients under dupilumab or other systemic immunomodulator treatment: a retrospective study**
TALLAL S, OELLERICH S, GUTERMUTH J, Ní DHUBHGHAILL S

124 **Inherited Limbal Stem Cell Deficiency as the Presenting Feature of PAX6-Related Aniridia**
TALLAL S, BLEYEN I, Ní DHUBHGHAILL S

125 **Leukemic optic neuropathy as first sign of leukaemia: a case-report**
SCHEPERS E, DEGHISLAGE C

126 **Preseptal cellulitis turning into necrotizing fasciitis: a pediatric emergency**
LE A, WALID BENLMOSTAPHA WB, RAYANN CHAMAS RC, EDWARD BOUTREMANS EB

127 **Bilateral Diffuse Preretinal Deposits in a patient with diabetic tractional retinal detachments**
SAAB C, LARUELLE G, BUGHIN A

128 **Beyond mitochondrial DNA: a POLG-related LHON phenotype**
BERGHMANS L, DE BAERE E, POPPE B, HEMELSOET D, VAN DE SOMPELE S, DE ZAEYTIJD J

129 **Bilateral diffuse uveal melanocytic proliferation (BDUMP) revealing lung adenocarcinoma**
EL KORTOBI S, BUGHIN A, GUESSOUS Y, BARTOSZEK P, KOZYREFF A

130 **In Vitro Comparative Evaluation of Autologous Serum Enhanced with Amniotic Membrane Extract Eye Drops (ASRAM) for Persistent Corneal Defects**
DAOUDI I, AFIFI Y, HAKAMI S, MOUJANE F, MOTULSKY E

131 **Subretinal Amniotic Membrane Graft for a Refractory Giant Full-Thickness Macular Hole**
RIVERA PROAÑO E, LARUELLE G, COCHE A

132 **Silent Sinus Syndrome Presenting as Apparent Contralateral Proptosis: A Diagnostic Pitfall**
RENARD N, VAN DE VEIRE S

133 **Unilateral Epiphora as the Presenting Sign of a Maxillary Sinus Fungus Ball**
RENARD N, VANDELANOTTE S, VAN DE VEIRE S

134 **Bilateral ocular surface inflammation during dupilumab therapy**
KEYTSMAN E, SALMAN S A

135 **Intravitreal aflibercept and laser therapy in the treatment of retinopathy of prematurity; retrospective cohort study over 2,5 years**
DE VETTER S, VERDONCK T, VAN ZEEBURG EJT

136 **Decoding growth factor profiles of platelet-derived eye drops for ocular surface disease: a systematic review of preparation, preservation and comparison with serum eye drops.**
COOLS L, ORBIE S, VAN REMOORTEL H, SIX KR, FEYS HB, SAELENS IEY, DELBEKE H

137 **Driving Forces and Perceived Barriers for the Adoption of Novel Endothelial Cell Therapies: An International Survey of Corneal Surgeons**
LUAN Y, Ní DHUBHGHAILL S, ROSE-NUSSBAUMER J, DE KORT C, ROMANO V, OELLERICH S

138 **Visual, Refractive and Tomographic Outcomes After Mitomycin-Free Manual Superficial Keratectomy for Salzmann Nodular Degeneration and Peripheral Hypertrophic Subepithelial Corneal Degeneration: A Retrospective Cohort Study**
HOUBEN I, MOURISSE S, DERVEAUX T, VAN GREMBERGHE I, KREPS E, ROELS D

139 **From Legs to the Eye: A Potential Corneal Manifestation of X-linked Ichthyosis**
ZEYEN A, SAELENS I, DELBEKE H

140 **Evaluation of the iStent Inject® W trabecular micro-bypass stent combined with cataract surgery in cases of controlled chronic open-angle glaucoma – Results at 1 year**
LESOINNE P, DUPONT G, GUILLAUME S, COLLIGNON N

141 **Predictive Value of OCT Biomarkers in Patients with Persistent Diabetic Macular Edema Undergoing Cataract Surgery Combined with a Dexamethasone Intravitreal Implant**
LAZAAR M, PROF FASOLINO

142 **Exploring topical losartan for corneal scarring: which scars show regression?**
AMELI S, KROLO I, OELLERICH S, NÍ DHUBHGHAILL S

Ahzantive®

40 mg/ml Injectable solution

(aflibercept)

Ahzantive®: ambulatory price

Prefilled syringe: €292,84

New from May 2026!





Best-in-class pre-filled syringe[2] containing an extractable volume of at least 0.09ml[1]

Free from silicone oil due to innovative i-coating™ technology[2]

Easy-to-handle design[2]

Ensuring dose accuracy[2]

Ahzantive® (Aflibercept Biosimilar)

Silicone Oil-FREE PFS[2]

Optimized for patient safety[2]

Ready & Easy for Intravitreal Injection[2]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

NAME OF THE MEDICINAL PRODUCT: Ahzantive 40 mg/mL solution for injection in pre-filled syringe. **QUALITATIVE AND QUANTITATIVE COMPOSITION:** 1 mL solution for injection contains 40 mg aflibercept*. One pre-filled syringe contains an extractable volume of at least 0.09 mL, equivalent to at least 3.6 mg aflibercept. This provides a usable amount to deliver a single dose of 0.05 mL containing 2 mg aflibercept. *Fusion protein consisting of portions of human VEGF (vascular endothelial growth factor) receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology. Excipient with known effect: Each mL solution for injection contains 0.3 mg polysorbate 20 (E 432). For the full list of excipients, see section 6.1. **CLINICAL PARTICULARS: Therapeutic indications:** Ahzantive is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), • visual impairment due to diabetic macular oedema (DME) (see section 5.1), • visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1). **Posology and method of administration:** Ahzantive is for intravitreal injection only. Ahzantive must only be administered by a qualified physician experienced in administering intravitreal injections. Posology: wet AMD: The recommended dose for Ahzantive is 2 mg aflibercept, equivalent to 0.05 mL. Ahzantive treatment is initiated with one injection per month for three consecutive doses. The treatment interval is then extended to two months. Based on the physician's judgement of visual and/or anatomic outcomes, the treatment interval may be maintained at two months or further extended using a treat and extend dosing regimen, where injection intervals are increased in 2 or 4 weekly increments to maintain stable visual and/or anatomic outcomes. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. There is no requirement for monitoring between injections. Based on the physician's judgement the schedule of monitoring visits may be more frequent than the injection visits. Treatment intervals greater than 4 months or shorter than 4 weeks between injections have not been studied (see section 5.1). *Macular oedema secondary to RVO (branch RVO or central RVO)*: The recommended dose for Ahzantive is 2 mg aflibercept equivalent to 0.05 mL. After the initial injection, treatment is given monthly. The interval between two doses should not be shorter than one month. If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, Ahzantive should be discontinued. Monthly treatment continues until maximum visual acuity is achieved and/or there are no signs of disease activity. Three or more consecutive, monthly injections may be needed. Treatment may then be continued with a treat-and-extend regimen with gradually increased treatment intervals to maintain stable visual and/or anatomic outcomes, however there are insufficient data to conclude on the length of these intervals. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. The monitoring and treatment schedule should be determined by the treating physician based on the individual patient's response. Monitoring for disease activity may include clinical examination, functional testing or imaging techniques (e.g. optical coherence tomography or fluorescein angiography). *Diabetic macular oedema*: The recommended dose for Ahzantive is 2 mg aflibercept equivalent to 0.05 mL. Ahzantive treatment is initiated with one injection per month for five consecutive doses, followed by one injection every two months. Based on the physician's judgement of visual and/or anatomic outcomes, the treatment interval may be maintained at 2 months or individualized, such as with a treat and extend dosing regimen, where the treatment intervals are usually increased by 2 week increments to maintain stable visual and/or anatomic outcomes. There are limited data for treatment intervals longer than 4 months. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. Treatment intervals shorter than 4 weeks have not been studied (see section 5.1). The schedule for monitoring should be determined by the treating physician. If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, Ahzantive should be discontinued. *Myopic choroidal neovascularisation*: The recommended dose for Ahzantive is a single intravitreal injection of 2 mg aflibercept equivalent to 0.05 mL. Additional doses may be administered if visual and/or anatomic outcomes indicate that the disease persists. Recurrences should be treated as a new manifestation of the disease. The schedule for monitoring should be determined by the treating physician. The interval between two doses should not be shorter than one month. Special populations: *Hepatic and/or renal impairment*: No specific studies in patients with hepatic and/or renal impairment have been conducted with aflibercept. Available data do not suggest a need for a dose adjustment with Ahzantive in these patients (see section 5.2). *Elderly population*: No special considerations are needed. There is limited experience in patients older than 75 years with DME. *Paediatric population*: The safety and efficacy of Ahzantive have not been established in children and adolescents below 18 years of age. There is no relevant use of aflibercept in the paediatric population for the indications of wet AMD, CRVO, BRVO, DME and myopic CNV. Method of administration: Intravitreal injections must be carried out according to medical standards and applicable guidelines by a qualified physician experienced in administering intravitreal injections. In general, adequate anaesthesia and asepsis, including topical broad spectrum microbicide (e.g. povidone iodine applied to the periocular skin, eyelid and ocular surface), have to be ensured. Surgical hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent) are recommended. Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, sterile equipment for paracentesis should be available. Following intravitreal injection patients should be instructed to report any symptoms suggestive of endophthalmitis (e.g. eye pain, redness of the eye, photophobia, blurring of vision) without delay. Each pre-filled syringe should only be used for the treatment of a single eye. Extraction of multiple doses from a pre-filled syringe may increase the risk of contamination and subsequent infection. The pre-filled syringe contains more than the recommended dose of 2 mg aflibercept (equivalent to 0.05 mL solution for injection). The extractable volume of the syringe is the amount that can be expelled from the syringe and is not to be used in total. For the Ahzantive pre-filled syringe, the extractable volume is at least 0.09 mL. **The excess volume must be expelled before injecting the recommended dose** (see section 6.6). Injecting the entire volume of the pre-filled syringe could result in overdose. To expel the air bubbles along with excess medicinal product, slowly depress the plunger to **align the edge of the plunger dome (not the tip of the dome) with the dosing line on the syringe** (equivalent to 0.05 mL i.e. 2 mg aflibercept) (see sections 4.9 and 6.6). The injection needle should be inserted 3.5-4.0 mm posterior to the limbus into the vitreous cavity, avoiding the horizontal meridian and aiming towards the centre of the globe. The injection volume of 0.05 mL is then delivered; a different scleral site should be used for subsequent injections. After injection any unused product must be discarded. For handling of the medicinal product before administration, see section 6.6. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Active or suspected ocular or periocular infection. Active severe intraocular inflammation. **Undesirable effects:** Summary of the safety profile: A total of 3,102 patients constituted the safety population in the eight phase III studies. Among those, 2,501 patients were treated with the recommended dose of 2 mg. Serious ocular adverse reactions in the study eye related to the injection procedure have occurred in less than 1 in 1,900 intravitreal injections with aflibercept and included blindness, endophthalmitis, retinal detachment, cataract traumatic, cataract, vitreous haemorrhage, vitreous detachment, and intraocular pressure increased (see section 4.4). The most frequently observed adverse reactions (in at least 5% of patients treated with aflibercept) were conjunctival haemorrhage (25%), retinal haemorrhage (11%), visual acuity reduced (11%), eye pain (10%), cataract (8%), intraocular pressure increased (8%), vitreous detachment (7%), and vitreous floaters (7%). Tabulated list of adverse reactions: The safety data described below include all adverse reactions from the eight phase III studies in the indications wet AMD, CRVO, BRVO, DME and myopic CNV with a reasonable possibility of causality to the injection procedure or medicinal product. The adverse reactions are listed by system organ class and frequency using the following convention: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. All treatment-emergent adverse drug reactions reported in patients in phase III studies (pooled data of the phase III studies for the indications wet AMD, CRVO, BRVO, DME and myopic CNV) or during post-marketing surveillance: **Immune system disorders:** Uncommon: Hypersensitivity***. **Eye disorders:** Very common: Visual acuity reduced, Retinal haemorrhage, Conjunctival haemorrhage, Eye pain. Common: Retinal pigment epithelial tear*, Detachment of the retinal pigment epithelium, Retinal degeneration, Vitreous haemorrhage, Cataract, Cataract cortical, Cataract nuclear, Cataract subcapsular, Corneal erosion, Corneal abrasion, Intraocular pressure increased, Vision blurred, Vitreous floaters, Vitreous detachment, Injection site pain, Foreign body sensation in eyes, Lacrimation increased, Eyelid oedema, Injection site haemorrhage, Punctate keratitis, Conjunctival hyperaemia, Ocular hyperaemia. Uncommon: Endophthalmitis**, Retinal detachment, Retinal tear, Iritis, Uveitis, Iridocyclitis, Lenticular opacities, Corneal epithelium defect, Injection site irritation, Abnormal sensation in eye, Eyelid irritation, Anterior chamber flare, Corneal oedema. Rare: Blindness, Cataract traumatic, Vitritis, Hypopyon. Not known: Scleritis****. *Conditions known to be associated with wet AMD. Observed in the wet AMD studies only. **Culture positive and culture negative endophthalmitis. ***During the post-marketing period, reports of hypersensitivity included rash, pruritus, urticaria, and isolated cases of severe anaphylactic/anaphylactoid reactions. ****From post marketing reporting. *Description of selected adverse reactions:* In the wet AMD phase III studies, there was an increased incidence of conjunctival haemorrhage in patients receiving anti-thrombotic agents. This increased incidence was comparable between patients treated with ranibizumab and aflibercept. Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition. There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the aflibercept clinical trials in patients with AMD, DME, RVO and myopic CNV. Across indications no notable difference between the groups treated with aflibercept and the respective comparator groups were observed. As with all therapeutic proteins, there is a potential for immunogenicity with Ahzantive. Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Federal Agency for Medicines and Health Products - https://www.famhp.be/ - Pharmacovigilance Dept. - Website: https://www.famhp.be/en/notification_effets - e-mail: adr@fagg-afmps.be. **MARKETING AUTHORISATION HOLDER:** Formycon AG, 82152 Martinsried/Planegg, Germany. **MARKETING AUTHORISATION NUMBER(S):** EU/1/24/1888/002. **SUPPLY:** Medicinal product subject to medical prescription. **DATE OF REVISION OF THE TEXT:** 06/2026. Detailed information on this medicinal product is available on the website of the European Medicines Agency https://www.ema.europa.eu.

References: 1. Ahzantive SmPC (last version) 2. Terumo/Conguence. Optimising microlitre dosing: Case study with intravitreal injection. One Drug Delivery. 2023: 44-49.

AHZ-BE-00012 - Teva Pharma Belgium

Date of approval Oct 2026

teva

INTERACTIVE CLINICAL COURSES

INTERACTIVE CLINICAL COURSE

WEDNESDAY | 09:00 - 10:30 | HALL 100

ICC 1:
Astigmatism correction during cataract surgery

Intermediate

Golenvaux Benoît, Sallet Guy, Van Cauwenberge Françoise
Centre Hospitalier Delta (Chirec), Brussels - Ooginstituut, Aalst - C.H.U. du Sart Tilman, Liège

This course aims to provide pragmatic and comprehensive information on surgical correction of astigmatism in cataract surgery. The new format will retain essential theoretical information, and provide more documented clinical-cases to evolve towards intermediate/advanced level. Debatable indications, unexpected refractive outcomes, complications and secondary corrections in toric surgery will be interactively presented and discussed.

09:00 **Astigmatism: Basics**
GOLENVAUX B

09:06 **Corneal Astigmatism Measurement**
SALLET G

09:12 **Axis registration: instruments, technologies, procedures**
GOLENVAUX B

09:19 **Surgery: Incisional**
GOLENVAUX B

09:26 **Surgery: Toric IOL's, Femto AK**
SALLET G

09:33 **Toric IOL's - indications, ESCRS guidelines, special TIOL's**
GOLENVAUX B

09:40 Q&A

09:45 **Clinical Cases**
VAN CAUWENBERGE F

10:00 **Clinical Cases**
SALLET G

10:14 **Clinical Cases**
GOLENVAUX B

10:27 *Q&A - Conclusions*

10:30 *End of ICC*

dd09-11-2026 see program online for the most update version

INTERACTIVE CLINICAL COURSE

WEDNESDAY | 09:00 - 10:30 | HALL 300

ICC 2:
Corneal topography made easy

Basic

Al-Sabai Nashwan, Koppen Carina
Focus Eye Clinic Wemmel and UZ Antwerpen

Corneal topography is a vital non-invasive imaging technique for ophthalmologists, particularly in the context of refractive surgery and the diagnosis of ectatic corneal diseases. This technique facilitates the detection of abnormalities, early disease diagnosis, classification, and effective disease monitoring. Our interactive course is designed to provide ophthalmologists with the essential knowledge and skills to proficiently utilize and interpret corneal topography in their clinical practice.

09:00 **Tomography**
KOPPEN C

09:45 **Clinical applications of tomography**
AL-SABAI N

10:30 *End of Interactive Clinical Course*

INTERACTIVE CLINICAL COURSE

WEDNESDAY | 14:00 - 15:30 | HALL 100

ICC 3:
READING BETWEEN THE LAYERS: Multimodal Retinal Imaging for Real-World Practice From Pattern Recognition to Clinical Judgment

Basic / Intermediate

Dirven Werner, De Zaeytijd Julie, Ruys Joke, Goethals Sebastien
AZ Turnhout, UZ Gent, New Vision Edegem, Oogartsenpraktijk Sint-Niklaas, UZ Gent, JessaHasselt, UZ Leuven

Every retinal image tells a story, but only if you know how to read it. This interactive course explores the principles and clinical use of OCT, OCT angiography, fundus autofluorescence, fluorescein angiography, and indocyanine green angiography, focusing on the imaging biomarkers, artifacts, and diagnostic pitfalls clinicians encounter daily.

Through real clinical cases and live audience discussion, participants will practice interpreting findings across modalities, weighing conflicting or ambiguous signals, and connecting imaging to clinical decision-making. The course moves beyond recognizing patterns toward building the judgment needed to use multimodal imaging confidently in everyday patiënt care.

14:00 **OCT in Retinal Disease: Lessons from Real Clinic Cases**
DE ZAEYTIJD J

14:20 **OCT-A Today: What It Really Adds to Your Daily Practice**
DIRVEN W

14:40 **Seeing Without Dye: What Autofluorescence Imaging Reveals in Everyday Practice**
RUYS J

15:00 **FA and ICGA in 2026: The Indications Where Dye Still Makes the Difference**
GOETHALS S

15:20 *Final Q&A*

15:30 *End of ICC*

This course will make use of Interactivity - Polling system

INTERACTIVE CLINICAL COURSE

WEDNESDAY | 16:00 - 17:30 | HALL 100

ICC 4:
Tumor, or not tumor, that is the question

Intermediate

Kairis Solène, Malaise Denis
C.H.U. Liège and Institut Curi Paris

Accurate diagnosis is fundamental in ocular oncology, where benign and pseudotumoral lesions often mimic malignancy. In this highly interactive course, experts in ocular oncology will present real-world cases from adult and pediatric practice involving the eyelids, anterior segment, and posterior segment. Through audience participation and multimodal imaging, participants will learn practical strategies to recognise tumors, avoid diagnostic pitfalls, and optimise patient management.

16:00 **Intraocular tumors**
KAIRIS S, MALAISE D

16:40 **Ocular surface tumors**
KAIRIS S, MALAISE D

17:10 **Retinoblastoma**
KAIRIS S, MALAISE D

17:30 *End of ICC*

This course will make use of Interactivity - Polling system

INTERACTIVE CLINICAL COURSE

THURSDAY | 09:00 - 10:30 | HALL 300

ICC 5:
Update on anterior segment: From Diagnosis to Modern Treatment

Basic

Saelens Isabelle, Heleen Delbeke, Emiel Matthys, Karolien Termote
UZ Leuven en UZ Brussel

Join us for an interactive educational course dedicated to the latest developments in the diagnosis, monitoring, and treatment of corneal disorders (keratoconus, Fuchs' endothelial dystrophy e.g.). Designed for general ophthalmologists and residents, this course combines scientific updates with practical clinical insights to support evidence-based decision-making in daily practice.

In addition, the course will provide an update on recent research and innovations in the anterior segment at the VUB and UZ Leuven.

09:00 **From Conefusion to Clarity: A Practical Update on Keratoconus**
MATTHYS E

09:22 **Redefining Corneal Rehabilitation: New Drops, Rings & Allografts**
TERMOTE K

09:44 **Finding Clarity in Fuchs**
SAELENS I

10:07 **Keeping an Eye on Innovation:**
Anterior Segment Research Updates from UZ Leuven
DELBEKE H

10:30 *End of ICC*

INTERACTIVE CLINICAL COURSE

THURSDAY | 11:00 - 12:30 | HALL 300

ICC 6:
Uveitis in Daily Practice

Intermediate

Sels Lise, Van Os Luc, Schauwvlieghe Pieter Paul and de la Porte Vincent
ZAS Cadix, UZ Leuven, UZ Antwerpen en AZ Monica

In this ICC, we will work through a series of clinical cases, discussing both typical and atypical presentations, diagnostic approaches, and treatment strategies.Can you recognise the warning signs? Do you know when treatment is indicated or when further investigation is required? This practical and interactive session focuses on clinical reasoning, providing insights and practical tools that can be applied directly in daily practice.

11:00 **Uveitis in Daily Practice - Case 1**
VAN OS L

11:20 **Uveitis in Daily Practice - Case 2**
SELS L

11:40 **Uveitis in Daily Practice - Case 3**
SCHAUWVLIEGHE P

12:00 **Uveitis in Daily Practice - Case 4**
DE LA PORTE V

12:20 *Closing remarks and questions*
12:30 *End of Interactive Clinical Course*

This course will make use of Interactivity - Polling system

INTERACTIVE CLINICAL COURSE

THURSDAY | 14:00 - 15:30 | HALL 300

ICC 7:
Precision Redefined: Fine-Tuning Refractive Surgery Outcomes

Intermediate

Goes Frank Jr., Goes William, Van Haecke Helena, Van Slycken Arnaud, Tack Michèle, Matthys Emiel
Goes Eye Centre, Oogcentrum Gent, Oogkliniek Oogust, Oogcentrum Tielt

Refractive surgery delivers excellent results today, yet the difference between good and outstanding lies in the details. In this course, we share how we work on those details in our daily practice. We cover diagnostics and patient selection, planning and execution, and how we track our own outcomes. One question guides every session: how can we do even better?

14:00 **Better diagnostics: beyond refraction**
GOES F

14:09 **Customization of laser profiles**
MATTHYS E

14:18 **Nomograms: from manufacturer settings to surgeon-specific refinement**
TACK M

14:27 **SMILE, LASIK, PRK, ICL: choosing the right procedure, not the fanciest one**
TACK M

14:36 **Astigmatism: the small details that matter**
MATTHYS E

14:45 **Centration strategy**
GOES F

14:54 **Optical zone, transition zone and night vision**
GOES W

15:03 **Ocular surface optimization before surgery**
VAN HAECKE H

15:12 **AI in screening, pattern recognition and procedure selection**
VAN SLYCKEN A

15:21 **AI in ICL vault prediction**
GOES W

15:30 *End of ICC*

INTERACTIVE CLINICAL COURSE

THURSDAY | 16:00 - 17:30 | HALL 300

ICC 8:
Beyond the Drops: Interventional Glaucoma for Better Quality of Life

Intermediate

Dr Sayeh Pourjavan, MD, PhD
Department of Ophthalmology, Hôpital Delta, CHIREC Hospital Group, Brussels
---
Prof. Nathalie Collignon, MD, PhD
Department of Ophthalmology, CHU de Liège, Liège

Glaucoma management is increasingly shifting toward earlier, more proactive intervention to reduce disease progression while maintaining patients' quality of life.
This course will focus on the practical implementation of interventional glaucoma management, from the early stages of the disease onwards. We will discuss when and how to use laser treatment, including SLT and YAG laser procedures, and how to integrate these techniques into the glaucoma treatment pathway. Particular attention will be given to when topical IOP-lowering therapy should be initiated or added, taking into account disease severity, risk of progression, treatment burden, adherence and quality of life.
Finally, the symposium will explore when medical and laser treatment are no longer sufficient and when to move towards MIGS, providing a practical, patient-centred approach to selecting and sequencing the available treatment options throughout the course of glaucoma.

16:00 **Interventional Glaucoma: The Basics**
POURJAVAN S

16:25 **Laser as a First-Line Treatment in Glaucoma**
COLLIGNON N

16:50 **Beyond Laser: Minimally Invasive Glaucoma Surgery**
POURJAVAN S, COLLIGNON N

17:15 *Interactive Discussions and Q&A*

17:30 *End of Interactive Clinical Course*

OB 2026
OPHTHALMOLOGICA BELGICA

WETLABS

dd09-11-2026 see program online for the most update version

WETLABS

The Phaco Wetlabs will teach you a basic understanding about cataract surgery. Standard procedures such as incision, sideports, capsulorhexis, phacopower, flow, vacuum, use of the foot pedal, and implant lens injection will be covered.

IMPORTANT:
Please note that it is compulsory to watch the theoretical phacodynamics video prior to attending the Phaco Wetlab at OB 2026. This video provides essential background knowledge and will ensure you are well-prepared for the practical session.
Completing this step is crucial to gaining a solid understanding and making the most of your hands-on experience at the wetlab.

HERE IS THE LINK TO WATCH THE VIDEO

WEDNESDAY | 14:00 - 15:30 | COPPER FOYER

Wetlab-2: Phaco beginners NL

Instructors: Dr. Dimitri Roels, Dr. Isabeau Houben

THURSDAY | 09:00 - 10:30 | COPPER FOYER

Wetlab-4: Phaco beginners NL

Instructors: Dr. Heleen Delbeke, Dr. Emiel Matthys

THURSDAY | 11:00 - 12:30 | COPPER FOYER

Wetlab-5: Phaco beginners NL

Instructors: Dr. Heleen Delbeke, Dr. Emiel Matthys

THURSDAY | 16:00 - 17:30 | COPPER FOYER

Wetlab-7: Phaco beginners FR

Instructors: Dr. Minh-Tri Hua, Dr. Anne-Catherine Stockman

---

dd09-11-2026 see program online for the most update version

WETLABS

WEDNESDAY | 09:00 - 10:30 | COPPER FOYER

Wetlab-1: Glaucoma (drylab)

Instructor: Dr Sayeh Pourjavan

WEDNESDAY | 16:15 - 17:45 | COPPER FOYER

Wetlab -3: Corneal Iris Sutures

Instructors: Dr François-Xavier Crahay

THURSDAY | 14:00 - 15:30 | COPPER FOYER

Wetlab-5: Glaucoma


Instructors: Dr. Sophie Lemmens, Dr. Kathy Hondeghem, Dr. Evelien Vandewalle

---

Easytocare
Your dose of health support

De partner in tarificatie en elektronische facturatie die het verschil maakt voor jou!

Je bent geen zorgverlener geworden om jouw avonden te slijten aan het opvolgen van betalingen, geweigerde prestaties, correcties en herindieningen, nietwaar?
Toch hoort die rompslomp nu eenmaal bij de facturatie van prestaties in derdebetaler. Gelukkig hoef je dat niet langer allemaal zelf te doen. Bij Easytocare nemen we die administratieve last met plezier van je over! Zo sta je er nooit alleen voor.



Zo maakt Easytocare het verschil voor jou:

- Wij verwerken jouw prestaties en controleren ze voordat ze naar de mutualiteiten vertrekken.
- Wij ontfermen ons over je volledige facturatie en volgen betalingen, weigeringen en rechtzettingen op.
- Wij houden de wettelijke verplichtingen en RIZIV-richtlijnen in de gaten.
- Jij kunt rekenen op vaste contactpersonen die vertrouwd zijn met jouw situatie.
- Wij nemen het contact met de mutualiteiten en de opvolging van je over.
- Dankzij prefinanciering weet je elke maand wanneer je uitbetaald wordt.
- Heldere prestatie- en betaaloverzichten zorgen ervoor dat je steeds weet waar je staat.
- Elektronische facturatie kan bij ons heel makkelijk met ons eigen verwerkingsprogramma easyTar.


Easytocare staat voor je klaar!

Heb je een vraag of wil je weten hoe Easytocare jou kan ondersteunen?
Werk je nog niet met ons verwerkingsprogramma easyTar en ben je benieuwd naar de mogelijkheden? Contacteer ons via **info@easytocare.be** of bel naar **011 28 78 03**.
Wij helpen je met veel plezier!

Easytocare
Your dose of health support

Le partenaire en tarification et facturation électronique qui fait la différence pour vous !

Vous n'êtes pas devenu professionnel de santé pour passer vos soirées à assurer le suivi des paiements, des prestations refusées, des corrections et des réintroductions, n'est-ce pas ? Pourtant, ces démarches fastidieuses font partie intégrante de la facturation des prestations en tiers payant. Heureusement, vous n'avez plus à vous occuper de tout cela vous-même. Easytocare se fait un plaisir de vous décharger de cette charge administrative ! Ainsi, vous n'êtes jamais seul.



Voici comment Easytocare fait la différence :

- Nous traitons vos prestations et les vérifions avant de les transmettre aux mutualités.
- Nous assurons le suivi des paiements, des refus et des rectifications.
- Nous veillons au respect des obligations légales et des directives de l'INAMI.
- Vous pouvez compter sur des interlocuteurs fixes qui connaissent bien votre situation.
- Nous prenons en charge les contacts avec les mutualités ainsi que le suivi de vos dossiers.
- Grâce au préfinancement, vous savez chaque mois à quelle date vous serez payé.
- Des relevés clairs des prestations et des paiements vous permettent de toujours savoir où vous en êtes.
- La facturation électronique est très facile chez nous grâce à notre propre logiciel de traitement easyTar.

Easytocare est à votre service !

Vous avez une question ou souhaitez savoir comment Easytocare peut vous accompagner ? Vous n'utilisez pas encore notre programme de traitement easyTar et souhaitez en découvrir les possibilités ? Contactez-nous à l'adresse **info@easytocare.be** ou appelez le **011 28 78 03**. Nous vous aidons avec plaisir !

Commercial sessions in the speakers corner

Commercial Short Presentations

WEDNESDAY

SPEAKERS CORNER

10:30 - 11:00 | HASA OPTIX

13:30 - 14:00 | COOPERVISION

15:30 - 16:00 | LUCE CARE

THURSDAY

SPEAKERS CORNER

10:30 - 11:00 | LUCE CARE

13:00 - 13:30 | SJJ SOLUTIONS

13:30 - 14:00 | COOPERVISION

15:30 - 16:00 | LAMÉRIS BELGIUM

FRIDAY

SPEAKERS CORNER

10:30 - 11:00 | THÉA PHARMA

12:30 - 13:00 | HASA OPTIX

13:30 - 14:00 | MEDIC CLEAN AIR

15:30 - 16:00 | MEDIC CLEAN AIR

dd09-11-2026 see program online for the most update version



HASA OPTIX
Belgium

COME AND LISTEN

Nothing in a cataract set should end in an **incinerator.**

Join us at Speaker's Corner to hear how single use instruments are being recycled today, country by country.

THE TALK

Closing the **loop**

Recycling single use instruments at scale. The HASA Recycle project.

WHEN	TIME	SPEAKER
Wednesday 25/11/2026	10:30 – 11:00	Victor Buisseret Sustainability & Circularity, HASA OPTIX Belgium

We look forward to seeing you!

HASA OPTIX
Belgium

OPHTHALMOLOGIA BELGICA 2026 · TWO TALKS BY LUCE CARE

Consolidation is here. The question is who owns it.



Belgian eye care is consolidating — with or without us. Two sessions on how the next chapter can still be built, and owned, by ophthalmologists themselves.

FOR OPHTHALMOLOGISTS, BY OPHTHALMOLOGISTS

WEDNESDAY 25 NOVEMBER · 15:30 – 16:00

Luce Care, your alternative to private equity

Dr. Guy Sallet · founder, Luce Care
Dr. Stefaan Reynders · Luce Care

Of the three national ophthalmology networks, two now answer to owners who are not ophthalmologists. Starting from the four questions every consolidated group is judged on — valuation, incentives, clinical autonomy and exit horizon — this talk shows how scale delivers its real benefits without an outside investor. For the colleague starting out, and for the colleague who leads an established group.

IN ENGLISH

THURSDAY 26 NOVEMBER · 10:30 – 11:00

Why I stepped into the Luce Care story

Dr. Greet Coppens · Luce Care

A personal account from the inside. Greet Coppens ran a family practice spanning three generations of ophthalmologists, most recently together with her parents. When succession and continuity came into view, they chose a network owned by ophthalmologists over a corporate or private-equity buyer. The doubts beforehand, the protections negotiated — and what changed after joining, as well as what did not.

IN ENGLISH

4
practices on 3 sites: Aalst, Ostend and Sint-Idesbald

17
self-employed ophthalmologists and 29 staff

100%
of the shares held by practising ophthalmologists

Luce Care

Your alternative to private equity.
Come and find us at the congress, or visit **lucecare.be**

Silicone oil in intravitreal injections

Why we replaced the lubricant



DATE
Thursday 26 November

TIME
13:00 – 13:30

LOCATION
Speakers Corner

About the session

Silicone oil used to lubricate syringes can end up in the vitreous after intravitreal injection and may cause side effects. This talk summarises what is known about how often this occurs and where the droplets come from (syringe, needle and handling). It explains why syringe lubrication is needed in the first place, and why SJJ Solutions chose to replace silicone oil as the lubricant in its syringe. The session closes with what the current evidence does and does not show, and practical points for syringe selection and injection preparation.

Speaker

Bas van Hal

Scientific & Professional Affairs
SJJ Solutions

What you will take away

- The extent and causes of silicone oil in the vitreous after intravitreal injection
- Why lubrication is needed, and the considerations in replacing silicone oil
- Practical points for choosing syringe and needle, and for preparing the injection

NORLASE®

LAMÉRIS

OB 2026 • SPEAKERS CORNER

SOLVING THE GLOBAL RETINA BOTTLENECK

How Norlase's portable laser platform scales access without scaling cost.



LYNX



ECHO



LION



LEAF

30-MINUTE INDUSTRY SESSION

Ophthalmology is a specialty that is facing the greatest shrinkage in its workforce. At the same time, there is an increasing burden of diabetes and glaucoma worldwide. Norlase's industry-first laser innovation empowers clinicians with adaptable solutions that maximize efficiency and improve patient care across clinical settings.



Kathrin Benedikt
Regional Director, Europe

25-27 November 2026
Square Brussels Meeting Centre
Brussels, Belgium

HASA OPTIX
Belgium

COME AND LISTEN

Two eyes, **two sets**

The case for bilateral sets in cataract and refractive surgery





FIRST EYE

Set A

SECOND EYE

Set B

Join us at Speaker's Corner to hear how Immediate Sequential Bilateral Cataract Surgery (ISBCS) can benefit you and your hospital.

WHEN

Friday 27/11/2026

TIME

12:30 – 13:00

SPEAKER

Eric T'Scharner

CEO, HASA OPTIX

We look forward to seeing you!

HASA OPTIX
Belgium

Ontwikkelen van een extramurale praktijk: Praktische inzichten en oplossingen

Hoe creëert u een **efficiënte extramurale praktijkruimte** die klaar is voor de toekomst?

- Concrete tips over indeling, ISO classificatie en rendement
- Hoe het juiste bouwteam het verschil maakt



Speakers Corner

Vr 27/11	13:30-14:00
Vr 27/11	15u30-16:00

Quality Living
expert in medische praktijken

Medic Clean Air

Industry Symposia

WEDNESDAY ACCESS MD'S only

ROOM SILVER

17:30 - 18:30 | AMGEN

THYROID EYE DISEASE
Beyond the eyes: the burden, the patient journey and what is changing

Dr. Virginie Ninclaus – Ophthalmologist, UZ Gent
Prof. Dr. Maria-Cristina Burlacu – Endocrinologist, CU Saint Luc Brussels
Dr. Patricia Delbeke – Paediatric Ophthalmologist, UZ Gent – Moderator & Patient Journey

THURSDAY

ROOM 100

07:45 - 08:45 | SANTEN ACCESS MD'S only

BREAKFAST SYMPOSIA

Catiolanze®
IOP control while keeping an eye on the ocular surface.

The impact of glaucoma treatment on the ocular surface.
Professor H. Delbeke, UZ Leuven
The science behind Catiolanze®: phase III evidence and cationic emulsion technology.
Professor I. Stalmans, UZ Leuven

FRIDAY

ROOM 100

07:45 - 08:45 | GLAXOSMITHKLINE ACCESS MD'S only

BREAKFAST SYMPOSIA

RECOGNISING AND MANAGING OCULAR ADVERSE EVENTS OF MODERN CANCER THERAPIES

PROF. DR. SORCHA NI DHUBHGHAILL
PROF. DR. HELEEN DELBEKE

INVITATION

AMGEN

OB 2026 LIVE IN SQUARE BRUSSELS
OPHTHALMOLOGICA BELGICA 25-27 Nov, 2026



OB 2026 | EXPERT-LED DISEASE UPDATE

THYROID EYE DISEASE

Beyond the eyes: the burden, the patient journey and what is changing

Also called Graves' orbitopathy (GO) or Graves' ophthalmopathy; sometimes referred to as Basedow's ophthalmopathy.

WEDNESDAY 25 NOVEMBER 2026 **17:30-18:30**
Square Brussels Meeting Centre | Room: SILVER

MAKE TIME FOR TED

TED can affect visual function, appearance and quality of life.[1,2]

RECOGNISE
Build confidence in recognising TED and its presentations.

UNDERSTAND
Explore disease burden and the patient journey.

DISCOVER
Review recent advances and innovations in TED care.

Learn from ophthalmology, endocrinology and patient-journey expertise

Dr. Virginie Ninclaus



Ophthalmologist - UZ Gent

SPEAKER

Prof. Dr. Maria-Cristina Burlacu



Endocrinologist - CU Saint Luc Brussels

SPEAKER

Dr. Patricia Delbeke



Paediatric Opthalmologist - UZ Gent

MODERATOR & PATIENT JOURNEY

Join the conversation at OB 2026 Add this symposium to your programme

[1] Bartalena L, et al. 2021 EUGOGO clinical practice guidelines. Eur J Endocrinol. 185:G43-G67.
[2] Burch HB, et al. 2022 ATA/ETA consensus statement. Thyroid. 32:1439-1470.
TED assessment considers visual function and quality of life; see cited guidelines.

R.E.: nv Amgen sa Telecomlaan 5-7, 1831 Diegem - BEL-632-26-80026 – V1.0 – creation date 7 Oct 2026

Invitation to the Santen Catiolanze® symposium



Catiolanze®:

IOP control while keeping an eye on the ocular surface.

Thursday 26 November 2026
from 7.45 am to 8.45 am*

Venue: SQUARE Brussels Meeting Center
Room: Hall 100

7.45 – 8.15 The Impact of glaucoma treatment on the ocular surface.

Professor H. Delbeke, UZ Leuven

8.15 – 8.45 The science behind Catiolanze®: phase III evidence and cationic emulsion technology.

Professor I. Stalmans, UZ Leuven

*Breakfast will be provided for participants.

Santen

Santen SA, the Netherlands Branch • De Entree 11-97 (18th floor)
1101 BH Amsterdam • Tel 036 3030060 • www.santen.eu

Created in October 2026. CATIOL-BE-260004.

Accreditation at OB 2026

OB 2026 is accredited through RIZIV/INAMI and offers participants the opportunity to obtain both general accreditation points and Ethics accreditation points during the congress.

AOB aims to make the accreditation process as clear and straightforward as possible. To ensure that your attendance is correctly registered and your accreditation points can be processed smoothly, please follow the procedures below.

General accreditation – Congress attendance

Accreditation for the regular scientific programme is registered per congress day attended.

Please scan your personal congress badge once each day in the Silver Foyer – the glass hallway leading towards the scientific session rooms.

The badge scan must be completed onsite and personally by the registered participant.

Accreditation can only be granted on the basis of attendance registrations completed personally and onsite. We therefore kindly ask participants not to share badges or complete an attendance registration on behalf of another participant.

Your badge will also be scanned when entering the lecture rooms.

Ethics accreditation – Friday sessions:

The two Ethics Sessions on Friday have a separate attendance procedure.

To receive accreditation for an Ethics Session, participants must be present in the session room and complete two QR scans during that session.

The QR codes will appear on the main screen in the session room at random moments during the session.

This means:
2 QR scans are required for each Ethics Session
4 QR scans are required in total if you attend both Ethics Sessions
Both scans for a session must be successfully registered to receive the corresponding accreditation points.
Please make sure you arrive on time and have your phone charged and connected to the internet, either through your own mobile connection or the venue Wi-Fi.

When completing the QR form, please carefully check that your details — in particular your name and RIZIV/INAMI number — are entered correctly.

Check your confirmation
Following each successful QR registration, you will immediately see **a green confirmation tick** on your phone.

Please make sure you received this confirmation message after you submitted the form. It confirms that your registration has been successfully received.

If you experience a technical problem with a scan, please inform the congress team immediately, while we still have the opportunity to assist you onsite.

Attendance registrations are personal and onsite
Accreditation can only be granted on the basis of attendance registrations completed personally, onsite and at the required time.

Registrations that do not meet these conditions cannot be accepted as confirmation of attendance.

We therefore kindly ask participants not to share attendance links, QR codes or badges, or to complete an attendance registration on behalf of another participant.

Similarly, photographs of the session room or confirmation from colleagues cannot replace the required attendance registration. The successfully registered attendance scans are the basis on which AOB can validate attendance and allocate the corresponding accreditation points.

Thank you for your cooperation
By completing the required registrations correctly, you help us ensure that your accreditation points can be processed accurately and smoothly after the congress.

Attend the relevant programme, complete the required scans onsite, and AOB will take care of the accreditation processing afterwards.

Thank you for your cooperation.